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Response To Stress By The Tumor Microenvironment
Abstract
Fibroblasts are typically quiescent and tumor suppressive in adult mammals but secrete factors upon
activation in benign and malignant diseases such as wound healing and tumor growth1. As residents of
the tumor microenvironment (TME), fibroblasts are subjected to the same stresses that tumor cells
experience including nutrient deprivation that activates the integrated stress response (ISR) pathway. This
eventually leads to either apoptosis due to intense or prolonged stress or autophagy to promote cellular
survival in the absence of essential nutrients2–5. Studies have shown that nutrient deprivation also
activates the tumor suppressor p53 in fibroblasts. However, little is known about the role of other tumor
suppressors such as the INK4a locus of the CDKN2A gene, the second most commonly mutated tumor
suppressor gene in human cancers6–8. The INK4a locus encodes two tumor suppressor genes including
the p19 Alternative reading frame (p19Arf) that activates p53 by sequestering the ubiquitin ligase MDM2.
While P19Arf regulation has been well characterized in cancer cells, its role in the TME has not been
investigated. Endothelial cells in the TME are also subjected to stress such as shear stress that is altered
upon changes in blood flow as a consequence of tumor vascularization as well as activities such as
aerobic exercise. Exercise is commonly prescribed to cancer patients to enhance quality of life however,
the effect of exercise during chemotherapy has not been extensively investigated. My work shows that
the growth of transplanted tumor cells in the flank of mice is significantly upregulated in p19Arf-/- mice as
compared to wild-type littermate controls indicating a role for P19Arf in the TME. My studies show that
primary murine adult lung fibroblasts (ALFs) induce P19Arf expression upon nutrient deprivation and that
prolonged leucine deprivation triggers apoptosis in wild-type ALFs. However, p19Arf-/- ALFs demonstrate
enhanced proliferation, migration and survival in response to long-term leucine deprivation due in part to
upregulation of the ISR pathway and increased autophagic flux. My data also suggests that loss of p19Arf
in fibroblasts promotes survival during nutrient deprivation through increased proliferation and autophagy.
My studies investigating the effect of acute aerobic exercise on endothelial cell activation and
subsequent tumor vascular normalization show that a single round of acute exercise enhances
chemotherapeutic efficacy when administered after exercise in melanoma xenograft tumor models
independent of tumor vascular normalization. My data suggests that acute exercise may provide an
opportunity to enhance chemotherapeutic efficacy.

Degree Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Graduate Group
Cell & Molecular Biology

First Advisor
Sandra W. Ryeom

Keywords
Endothelial Cell, Exercise, Fibroblast, Integrated Stress Response, p19Arf, Tumor Microenvironment

Subject Categories
Cell Biology
This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/4240

RESPONSE TO STRESS BY THE TUMOR MICROENVIRONMENT
Kerry Roby
A DISSERTATION
in
Cell and Molecular Biology
Presented to the Faculties of the University of Pennsylvania
in
Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
2021

Supervisor of Dissertation

_____________________
Dr. Sandra Ryeom
Associate Professor, Cancer Biology

Graduate Group Chairperson
_______________________
Dr. Daniel Kessler,
Associate Professor, Cell and Developmental Biology

Dissertation Committee
Chair: Dr. Costas Koumenis, Professor of Research Oncology, Department of Radiation
Oncology
Dr. Donita Brady, Presential Assistant Professor, Department of Cancer Biology
Dr. Yi Fan, Associate Professor, Department of Radiation Oncology
Dr. Ellen Puré, Grace Lansing Lambert Professor, Department of Biomedical Science

Dedication page
To my ancestors and those that will follow after me, thank you for dreaming and
believing. This is for you Mama.

ii

ACKNOWLEDGMENT
I would not have made it to the end of my degree without all the support,
mentorship, and encouragement I received from my mentors, thesis committee,
labmates, friends, and most importantly, family. Individually naming people is a sure-fire
way to forget someone important – so I am acknowledging everyone who touched my
life, big or small, over the past 7 years. Thank you for your unconditional love and
support, and for believing in me even when I did not believe in myself.
That having been said, I would like to thank my mentor, Dr. Sandra Ryeom, for
your mentorship, guidance, advocacy, and patience throughout the
course of my PhD. You are such incredible role model, and I’m very lucky to have had
the opportunity to study and work in your laboratory.
Thanks also go to Tiffany Tsang of the Brady Lab, Ioannis Verginadis of the
Koumenis Lab, and Keri Schadler, Bang Jin Kim, Allyson Lieberman, Nicole Zaragoza
Rodriguez, Rebecca Hoffman, and Jacob Till of the Ryeom lab for their guidance,
assistance with experimental design, technique, and protocol, with special thanks to Keri
Schadler for believing in and mentoring me from my first experience in the Ryeom lab. I
acknowledge all my thesis committee members, past and present, for their invaluable
expertise and faith in me as a student and scientist.
Thank you to the Biomedical Graduate Studies Office of Research Diversity and
Training for the opportunity to begin my research journey through the PREP program,
the opportunity to mentor future researchers, and the support as I’ve matured as a
scientist. Finally, I would like to acknowledge and thank my funding from the Diversity
Supplement through the National Cancer Institute.

iii

ABSTRACT
RESPONSE TO STRESS BY THE TUMOR MICROENVIRONMENT
Kerry Roby
Sandra Ryeom

Fibroblasts are typically quiescent and tumor suppressive in adult mammals but secrete
factors upon activation in benign and malignant diseases such as wound healing and
tumor growth1. As residents of the tumor microenvironment (TME), fibroblasts are
subjected to the same stresses that tumor cells experience including nutrient deprivation
that activates the integrated stress response (ISR) pathway. This eventually leads to either
apoptosis due to intense or prolonged stress or autophagy to promote cellular survival in
the absence of essential nutrients2–5. Studies have shown that nutrient deprivation also
activates the tumor suppressor p53 in fibroblasts. However, little is known about the role
of other tumor suppressors such as the INK4a locus of the CDKN2A gene, the second
most commonly mutated tumor suppressor gene in human cancers6–8. The INK4a locus
encodes two tumor suppressor genes including the p19 Alternative reading frame (p19Arf)
that activates p53 by sequestering the ubiquitin ligase MDM2. While P19Arf regulation has
been well characterized in cancer cells, its role in the TME has not been investigated.
Endothelial cells in the TME are also subjected to stress such as shear stress that is
altered upon changes in blood flow as a consequence of tumor vascularization as well as
activities such as aerobic exercise. Exercise is commonly prescribed to cancer patients to
enhance quality of life however, the effect of exercise during chemotherapy has not been
extensively investigated. My work shows that the growth of transplanted tumor cells in the
flank of mice is significantly upregulated in p19Arf-/- mice as compared to wild-type
iv

littermate controls indicating a role for P19Arf in the TME. My studies show that primary
murine adult lung fibroblasts (ALFs) induce P19Arf expression upon nutrient deprivation
and that prolonged leucine deprivation triggers apoptosis in wild-type ALFs. However,
p19Arf-/- ALFs demonstrate enhanced proliferation, migration and survival in response to
long-term leucine deprivation due in part to upregulation of the ISR pathway and increased
autophagic flux. My data also suggests that loss of p19Arf in fibroblasts promotes survival
during nutrient deprivation through increased proliferation and autophagy. My studies
investigating the effect of acute aerobic exercise on endothelial cell activation and
subsequent tumor vascular normalization show that a single round of acute exercise
enhances chemotherapeutic efficacy when administered after exercise in melanoma
xenograft tumor models independent of tumor vascular normalization. My data suggests
that acute exercise may provide an opportunity to enhance chemotherapeutic efficacy.
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CHAPTER 1: Introduction

Over 90% of all cancer related-deaths are due to metastatic progression9. Initial
studies investigating cancer treatment focused solely on the primary tumor, but in 1889
Dr. Stephen Paget introduced a concept that shifted our understanding of cancer
progression. Paget’s theory of metastasis suggested that upon entering the blood
stream, cancer cells (seeds) are selective in terms of the organ site where they will
metastasize and grow. He proposed that the landing site or colonization of circulating
metastatic cancer cells is regulated by the conditions in a distal organs
microenvironment (soil)10,11. The tumor microenvironment (TME) is the local area
surrounding the tumor cells consisting of different cellular populations that include
immune cells, endothelial cells, and fibroblasts as well as extracellular matrix proteins
(Figure 1.1).
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Figure 1.1: Cartoon depiction of the cellular populations in the tumor microenvironment.
The tumor microenvironment characteristically possesses aberrant tumor vasculature with
heterogeneous population of cells surrounding cancer cells, that include endothelial cells,
fibroblasts, and immune cells.

Cellular Populations in the Tumor Microenvironment
Immune Cells
In response to antigens expressed on the surface of tumor cells, immune cells,
such as CD8+ cytotoxic T lymphocytes, are primed and activated to induce cancer cell
death via the release of cytotoxic granules or Fas Ligand-mediated apoptosis12.
Activated T-cells proliferate rapidly to exert effector functions that require the
consumption of large amounts of nutrients and resources that are scarce in the TME,
such as amino acids. T-cells accomplish this by increasing the expression of amino acid
transporters on their cell surface that are required for different processes such as T-cell
2

activation, homeostasis, differentiation, and memory13. One particular amino acid
transporters is the L-type amino acid transporter 1 (LAT1) which is responsible for
transporting neutral amino acids including leucine, isoleucine, and valine into the cell14.
LAT1 has been shown to be highly expressed on cancer cells but expressed at low
levels on normal cells with the exception of activated T-cells. In activated human T-cells,
upregulation of LAT1 expression correlated with high cytotoxic cytokine production that
was abrogated when LAT1 was specifically targeted and deleted or inhibited using a
LAT1 selective inhibitor, JPH20315. While immune cells play vital roles in the
suppression of tumor growth through inducing apoptosis of cancer cells, a subset of
immune cells also promote tumorigenesis by creating an immunosuppressive TME
preventing the function of anti-tumor immune cell populations. For instance,
macrophages are part of the innate immune response that are activated and skewed
towards either a classical (M1) or alternative (M2) phenotype. M1 macrophages function
in an anti-tumor manner and are activated in response to IFN-g releasing proinflammatory cytokines, including TNF-a, and express MHC-I & II antigens to facilitate
phagocytosis of tumor cells16. In contrast, M2 macrophages are activated in response to
IL-4/IL-13 to inhibit the pro-inflammatory response by M1 macrophages and inhibit
cytotoxic T-cells through direct cell-cell interaction.16,17 In cancer, tumor associated
macrophages (TAMs) comprise as much as 50% of the tumor mass and typically
possess a M2 expression pattern. Although macrophages in the TME are often
described as having a distinct M1 or M2 phenotype, data suggests that macrophage
phenotypes exist on a continuum of macrophage polarization between M1 and M2 such
that the TME pivots tumor killing M1 macrophages towards tumor-promoting M2
macrophage phenotypes18. M2 macrophages of the TME promote tumor progression
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through suppression of pro-inflammatory cytokines such as IL-12 and IL-23, and the
increased expression of the catabolic arginine enzyme, arginase-116. Arginase-1
metabolizes arginine into ornithine and polyamines, precursors necessary for cellular
proliferation thus promoting tumor progression19. In efforts to enhance effector T-cell
function in cancer, immune checkpoint blockade therapies targeting the immune
checkpoint inhibitors, CTLA-4 and PD-1-PD-L1 are currently being utilized in the
treatment of many different cancer types with varying results from complete cure to lack
of efficacy in tumors such as melanoma20 and prostate cancer21, respectively.

Endothelial cells
The endothelial cell population in the TME play key roles in cancer progression.
Endothelial cells form new blood vessels during development and during tumor growth.
During development, vasculogenesis is the process of establishing new vasculature
during embryogenesis from bone marrow endothelial progenitor cells. In comparison,
during tumorigenesis, endothelial cells also form new blood vessels, but this process is
called neo-angiogenesis and is the generation of new blood vessels from existing
vessels to support tumor expansion. In response to signals from the tumor, such as
increased production of vascular endothelial growth factor (VEGF), endothelial cells
become activated, alter their secretome, proliferate, migrate and form vessels.
Endothelial cell activation leads to the degradation of basement membrane,
endothelial cell migration, proliferation, and differentiation leading to the formation of
blood vessels that contribute to promote tumor progression and metastasis22. Because
of the reliance of endothelial cells on VEGF for activation and angiogenesis, anti4

VEGF/VEGF receptor therapies have been a long-standing area of investigation and the
target of drug development to prevent tumor angiogenesis with the hopes that
preventing blood supply to tumor cells would inhibit cancer progression. The excitement
in targeting angiogenesis was in part due to the notion that this could be a universal
approach to treating cancer since it was assumed that endothelial cells were the same
regardless of the organ environment they resided. Thus, the ability to attenuate the
expansion of blood vessels would ‘starve’ any tumor, regardless of their organ site.
While effective in inhibiting tumor growth in vitro and in mouse models, the use of
anti-angiogenic therapy showed limited efficacy in clinical trials. The human VEGF
antibody, Bevacizumab, was shown to be effective in a limited number of cancer types
with improved overall and progression-free survival in colorectal, lung, kidney, and
glioblastoma when used in combination with other chemotherapies. Initially,
Bevacizumab was thought to show efficacy in treating metastatic disease as well.
However, side effects such as hypertension, thromboembolic events, ventricular
dysfunction, myocardial infarction, gastrointestinal perforation, and proteinuria23 showed
that the toxicity of Bevacizumab in combination with chemotherapy did not improve
overall survival. Some possible explanations for the lack of efficacy of anti-angiogenic
therapies include the assumptions that endothelial cells in the TME were genetically
stable and reliant solely upon VEGF for their activation. Further investigation into tumor
associated-endothelial cells identified that they may not be genetically stable with one
study indicating that tumor associated endothelial cells are aneuploid, harboring an
abnormal number of chromosomes24. Studies have also characterized the abnormal
function and structure of tumor blood vessels. While normal blood vessels are highly
organized and efficient in the circulation of blood, nutrients, and drugs throughout the
5

body, tumor blood vessels are inefficient conduits possessing disorganized, leaky
vasculature and blind-ending sprouts that prevent proper perfusion of the tumor reducing
effective drug delivery25. Studies have also demonstrated that some cancers become
resistant to anti-VEGF therapy resulting in continued tumor angiogenesis and tumor
progression26. Due to the significant level of circulating VEGF within the TME,
Bevacizumab treatment at doses that limit adverse side effects is insufficient to
effectively sequester circulating tumor-derived VEGF; this potentially allows for
endothelial cells to continue functioning using alternative growth factors along with low
levels of VEGF.
Aberrant vasculature is a common characteristic of the TME contributing to the
inefficacy of anti-angiogenic therapy as well as chemotherapy. Due to the constant
demand for nutrients in the TME and the increased VEGF secreted by tumor cells, tumor
blood vessels are generated rapidly and are immature resulting in an abnormal
vasculature. Normal blood vasculature consists of a mature, tightly organized endothelial
cell layer that is surrounded by basement membrane and pericytes such as smooth
muscle cells (Figure 1.2). In contrast, tumor vessels possess abnormal vasculature due
in part to the rapid proliferation of the endothelial cell population resulting in gaps in the
endothelial cell barrier making this newly generated vasculature leaky and fenestrated
(Figure 1.2)27.
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Figure 1.2: Cartoon of normal and tumor associated blood vasculature. Normal blood
vessels contain an endothelial cell layer with tight junctions and evenly distributed
extracellular matrix that is encased within a pericyte covering. In contrast, tumor blood
vessels are immature as they lack pericyte coverage, are highly disorganized and lack tight
junctions leading to a leaky endothelial cell layer. This leads to sporadic sprouting with
collapsed lumens and unevenly deposited extracellular matrix.

Leaky vessels also prevent even distribution of basement membrane and inefficient
pericyte coverage making these vessels stunted in their development with collapsed
lumens28. Due to the poorly constructed blood vessel network in tumors, the distribution
of chemotherapy or other targeted therapies for cancer treatment is relatively inefficient.
Dr. Rakesh Jain first described the concept of tumor vascular normalization through
sequestering VEGF and other pro-angiogenic proteins permitting maturation of the
vasculature by restoring the balance between pro- and anti-angiogenic proteins. The
decrease in pro-angiogenic protein such as VEGF suppresses endothelial cell
proliferation and migration allowing increased adhesion between endothelial cells and
pericyte coverage of blood vessels. It was proposed that tumor vascular normalization
leads to longer, more functional vessels with adequate lumens increasing blood flow and
providing a window to improve chemotherapeutic efficacy. In support of the concept of
tumor vascular normalization, Dickson, et al, showed that treatment of a mouse model of
neuroblastoma with a single dose of Avastin, a murine anti-VEGF sequestering antibody,
7

increased vessel maturation, drug penetrance, and trended towards a reduction in tumor
growth when used in combination with topotecan29. In addition, Winkler, et al, showed
that treatment with the VEGF2R antibody DC101, was effective in normalizing the tumor
vasculature of human glioblastoma xenografts resulting in a decrease in hypoxic
regions, increased pericyte coverage, and reduced basement membrane thickness
through increased degradation by matrix metalloproteinases30–33. While many studies
have investigated the use of anti-angiogenic therapies to promote tumor vasculature
normalization, the limited window and the adverse side effects indicate a need for other
approaches to normalize tumor vessels. Chapter 4 will discuss my work investigating
alternative approaches to tumor vascular normalization independent of pharmacologic
targeting.

Fibroblasts
Another major cellular population in the TME is the fibroblast. Fibroblasts are
typically quiescent cells that reside in the interstitial spaces of tissues. They become
activated in response to a variety of stimuli such as injury or activating signals such as
transforming growth factor-b (TGF-b)34. In response to injury such as a wound in the
skin, fibroblasts enter a reversible activation state where they become contractile and
migratory, and gain expression of markers including vimentin, and alpha smooth muscle
actin (a-SMA). Activated fibroblasts deposit extracellular matrix (ECM) components,
such as type I and IV collagens and also remodel the surrounding ECM through the
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Figure 1.3: Cartoon of stages of fibroblast activation. Fibroblasts are typically quiescent
and dormant within tissues. They become activated in response to stimuli, such as wound
healing, to remodel the extracellular matrix through the deposition of type I and IV collagens
and the secretion of matrix metalloproteinases that will clear existing matrix until the wound
is healed.

production of matrix metalloproteinases (MMPs) to degrade existing matrix, until the
wound is closed and has healed1. Tumors are often referred to as a wound that is unable
to heal35, due in part to the similarity between activated fibroblasts in wounds and the
activated state of fibroblasts in cancer (Figure 1.3).
Cancer associated fibroblasts (CAFs) have a similar phenotype and function as
normal fibroblasts but are considered to be constitutively activated. As a result of
increased and persistent production of TGF-b and other fibroblast activating factors by
cancer cells in the TME, CAFs are unable to return to a quiescent/resting state resulting
in their increased contractility, proliferation, migration, altered secretome and ECM
remodeling. CAFs remodel the ECM at higher rates as compared to activated normal
fibroblasts through the production of collagens as well as increased secretion of MMPs
that degrade and reorganize the ECM. CAFs remodel the ECM in a pro-tumorigenic
manner by secreting factors including hepatocyte growth factor (HGF), fibroblast growth
factor (FGF), and TGF-b which promote migration, invasion, and metastasis of cancer
9

cells36. Gaggiolli et al.,37showed that squamous carcinoma cells were able to migrate
through a matrix layer in a fibroblast dependent manner albeit through direct cell-cell
contact.
The identification of a specific CAF marker has been long sought after as both
normal fibroblasts and CAFs express a-SMA and vimentin. Studies now agree that the
cell surface receptor, fibroblast activation protein (FAP) may be the best marker for
CAFs as FAP expression is primarily upregulated on CAFs. FAP is a member of the
dipeptidyl peptidase (DPP) family of enzymes, sharing 50% homology with its closest
member, DPPIV.38 FAP
monomers become activated
through the formation of
homodimers or heterodimers
with other FAP monomers and
DPPIV monomers,
respectively38 (Figure 1.4). FAP
remodels components of the
ECM in response to injury, and
has been shown to increase the

Figure 1.4: Cartoon of Fibroblast Activation
Protein (FAP) activation on the cell surface. FAP
expression is upregulated on the surface of cancer
associated fibroblasts (CAFs). FAP monomers
(green) are inactive but are able to become active
through dimerization with other FAP monomers or
dipeptidyl peptidase (DPP) IV monomers.

expression of a-SMA, collagen
type I, and fibronectin39. FAP expression is typically low in normal tissue, but is
upregulated on CAFs in many different tumor types including pancreatic cancer, breast
cancer and lung cancer; it’s high expression is also associated with poor prognosis of
cancer patients40.
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With the identification of FAP as a relatively specific CAF marker, this has
presented a therapeutic option to target fibroblasts in the TME for cancer treatment. The
targeting of FAP expressing cells in an effort to suppress tumor growth has become an
area of active investigation. Genetic ablation or pharmaceutical inhibition of FAP in vivo
inhibited colon cancer tumor growth41 and lung cancer in mouse models42;
pharmacological inhibition of FAP with the GluBoroPro dipeptide, PT630, inhibits the
enzymatic functions of FAP and DPPIV and efficiently inhibited tumor growth in these
models. FAP’s expression within the tumor stroma has also led to the development of
chimeric antigen receptor (CAR) – T cells that are designed to target FAP+ cells. The use
of FAP specific CAR-T cells inhibited mesothelioma and lung cancer growth and
increased cytotoxicity within tumors in addition to ablating FAP+ cardiac fibroblasts in a
mouse model of cardiac fibrosis43,44.

Stress and the Tumor Microenvironment
As a result of the exponential proliferation rate of cancer cells, they sequester
resources for themselves triggering various stressors in the TME including hypoxia,
acidosis, and nutrient or amino acid deprivation. Due to the disorganized and inefficient
vasculature associated with a rapidly developing tumor, a common stress is the
restriction of oxygen or hypoxia. In response to hypoxia, stabilization of the transcription
factors hypoxia inducible factors (HIFs)45 occurs in both cancer and normal cells. The
oxygen-sensing subunit of HIFs, HIF-1a, dimerizes with HIF-1b to induce the
transcription of genes allowing cells to alter their metabolism into an aerobic glycolytic
state to continue the production of energy during low oxygen conditions46. The HIF-1a
11

subunit is kept at low levels during normoxia by its ubiquitination and proteasomal
degradation by the von Hippel-Lindau protein (pVHL). Specifically, HIF-1a becomes
hydroxylated by the oxygen-dependent proly-hydroxylase domain-containing proteins
(PHDs) at proline sites facilitating binding by pVHL45,47. HIF-1a expression is
upregulated in cancers and in the TME inducing changes in resident cellular populations
to support tumor progression, such as the transformation of fibroblasts to CAFs45. As a
consequence of increased hypoxia, cells of the TME cannot utilize oxidative
phosphorylation to produce energy from glucose. This results in the utilization of
anaerobic glycolysis which is an alternative method for cells to produce energy in
hypoxic environments, albeit at lower levels. Interestingly, cancer cells were discovered
to convert glucose into energy in a less efficient manner regardless of oxygen status,
which is termed the Warburg effect48. As a result of inefficient perfusion of the TME, both
anaerobic glycolysis and the Warburg effect expel high amounts of lactic acid into the
surrounding TME resulting in an acidic microenvironment49. Acidosis of the TME results
in metabolic reprogramming of cancer cells and CAFs alike to aid in tumor progression
and chemoresistance50. For instance, Hexokinase 2 (HK2) has been shown to be
upregulated in CAFs resulting in increased cell cycle progression and suppressed p27
expression51. Despite the acidic and hypoxic conditions of the TME, cancer cells
continue to rapidly proliferate sequestering nutrients resulting in nutrient deprivation
within the TME. Nutrient deprivation is a hallmark of cancer that forces cancer cells to
become scavengers to acquire the nutrients necessary to maintain their proliferation in a
stressful environment. Avagliano et al. suggest that CAFs in the TME become forced to
use the Warburg effect to produce high energy metabolites that cancer cells utilize to
maintain their proliferation52. In addition to metabolites, such as pyruvate and ketone
12

bodies, amino acids are a viable resource that are scarce and preferentially taken up by
rapidly proliferating cancer cells. Attempts to target enhanced amino acid consumption
has resulted in varying effects. While glutamine overconsumption is a common trait of
the TME, targeting the essential amino acid, leucine, can induce apoptosis of human
breast cancer cell lines53. To counter the stressful microenvironment, the integrated
stress response (ISR) pathway is an evolutionarily conserved pathway that evolved so
that cells could survive the effect of stressors ranging from viral infection, misfolded
proteins, acidosis and nutrient deprivation.
The Integrated Stress
Response Pathway
The core of the
ISR pathway consists of
a class of kinases that
are activated exclusively
in response to specific
stimuli (Figure 1.5). The
kinases heme-regulated
inhibitor eIF2a kinase
(HRI), double-stranded
RNA-dependent protein
kinase (PKR), PKR-like
ER Kinase (PERK), and
general control non-

Figure 1.5: Schematic of the Integrated Stress Response
Pathways. Kinases are activated in response to the indicated
stimuli to phosphorylate the eukaryotic initiation factor 2 alpha
(eIF2a) subunit resulting in 1) the inhibition of global
translation and 2) translation of specific proteins with conserved
upstream open reading frames such as activating transcription
factor 4 (ATF4). ATF4 transcribes genes generating nonessential amino acids or promoting autophagy. Prolonged stress
increases expression of the apoptosis inducing C/EBMP
homologous\protein (CHOP).General non-depressible protein 2
(GCN2), heme-regulated inhibitor (HRI), RNA-dependent
protein kinase (PKR), and PKR-like ER (PERK). Adapted from
Pakos-Zebrucka, et al,EMBO Reports 2016.

depressible protein 2 (GCN2) all converge to phosphorylate the eukaryotic initiation
13

factor 2 -alpha (p-eIF2a) subunit. This results in the halting of general protein translation
with the exception of genes including activating transcription factor 4 (ATF4). ATF4
transcribes genes that initially promote cell survival under stress including autophagy
related gene 5 (ATG5) to promote autophagy. However, when the stress is prolonged,
ATF4 transactivates genes that promote cell death including pro-apoptotic genes such
as C/EBMP homologous protein (CHOP).
The HRI arm of the pathway is activated in response to heme deprivation. In
normal conditions, heme binds both the N-terminus and kinase binding domain to keep
HRI inactive, but when heme is deprived HRI dimerizes to auto-phosphorylate itself to
become activate54. While the other arms of the ISR are broadly distributed between
tissues, HRI is found within erythroid cells and is required for erythrocyte differentiation
and regulating globin production55. In cancer, HRI can be both anti-tumor or tumor
promoting as it has been to shown to be regulated by the ternary complex inhibitor, N,N′diarylureas, to induce the phosphorylation of eIF2a and sequential increase in CHOP to
induce prostate cancer cell death and inhibit human prostate tumor growth56. In contrast,
its ablation in bortezomib resistant human prostate cancer cells sensitizes them and
induces cell death57.
The PKR arm of the pathway is activated in response to double stranded RNA
(dsRNA) that is typically associated with viral infection. When activated, PKR dimerizes
and auto-phosphorylates itself at threonine 446 to subsequently phosphorylate eIF2a. In
infections such as Hepatitis virus C (HCV), PKR levels are upregulated in response to
dsRNA as a result of the increased viral proliferation. Due to chronic infection, HCV
progresses and develops into liver cirrhosis and eventually hepatocellular carcinoma
(HCC) although the molecular mechanisms underlying this progression are not well
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characterized58. Hiasa et al, showed that PKR expression was increased in HCV-related
tumor regions when compared to non-tumor areas in patient samples suggesting a
requirement for PKR in HCV-related HCC59.
In response to ER stress, the unfolded protein response pathway becomes
activated involving the activation of inositol-requiring enzyme (IRE-1), ATF-6a, and the
ISR kinase, PERK. ER stress results from the accumulation of misfolded proteins that
arise due to mutations, oxidative stress, heat-shock, or dysregulated calcium flux. These
misfolded proteins allow for the PERK regulator, glucose regulated protein-78 (GRP78),
to dissociate from and release the PERK kinase allowing it to dimerize, autophosphorylate, and become activated54. In cancer, PERK and the unfolded protein
response pathway is required for tumor cell survival in hypoxic regions of tumors.
Rouschop et al, showed that colorectal cancer cells survive hypoxia through autophagy
in a PERK-dependent manner; they established that colorectal tumors with PERK
inhibition reduced hypoxic regions, reduced tumor growth, and showed increased
sensitivity to irradiation60. The ISR shows redundancy when one arm is targeted. For
example in a genetically engineered mouse model of sarcoma with a deletion of GCN2,
the level of eIF2a phosphorylation was maintained in Gcn2-/- tumors due to
compensation by PERK61.
The final arm of the ISR pathway, GCN2, is activated in response to amino acid
deprivation (AAD). In normal conditions, transfer ribonucleic acids (tRNA) are charged
by the corresponding amino acid allowing GCN2 to remain inactivated. However, when
cells are deprived of amino acids, tRNAs bind to GCN2 promoting a conformational
change that permits dimerization, autophosphorylation, and activation of the kinase54. In
addition to genes related to autophagy and apoptosis, GCN2-mediated activation of
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ATF4 induces the production of enzymes that generate non-essential amino acids, such
as asparagine, as needed by the cell. However, when the cell is deprived of essential
amino acids, ATF4 promotes autophagy to allow for the degradation of cellular
organelles to provide essential amino acids necessary for cell survival until the essential
amino acid pool is repleted and the pathway is then inactivated. GCN2 is distributed
among many tissue types and is required for cellular processes including cell
proliferation, autophagy4, and angiogenesis62 in response to AAD. As is common in the
TME, amino acids trigger activation of GCN2 in both normal cells and cancer cells. In
human cancer cell lines, GCN2 expression was upregulated and shown to be required
for production of VEGF and tumorigenesis while deletion of GCN2 reversed this
phenotype and reduced tumor growth rates63. Because of the double-edged sword that
the GCN2-ATF4 pathway
presents in cancer,
pharmacological approaches
to either activate or inactive
(Figure 1.6) the GCN2
pathway depending on the
cancer type and the target
population has been an area
of great interest54. Activators
of GCN2 raise the levels of
uncharged tRNAs through
sequestering amino acids,
such as asparagine by

Figure 1.6: Schematic of GCN2 pathway and
pharmacological activators and inhibitors of the
GCN2 kinase.. Pharmacological approaches have been
developed to induce the activation or inhibition of the
GCN2 kinase to be used in combination with other
therapies. Adapted from Pakos-Zebrucka, et al, EMBO
Reports 2016.

asparaginase, that subsequently bind and activate GCN2. Inhibitors of GCN2 function to
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inhibit the phosphorylation of eIF2a in response to GCN2 activating stimuli, but their
mechanism of action is not specific to GNC264.
The majority of work on the ISR has investigated its function in cancer cells, with
few studies investigating the role of the ISR in other cellular populations of the TME. The
GCN2/ATF4 pathway has been shown to be required for endothelial cell activation and
contribute to tumor progression. In response to AAD, GCN2 activation correlates with
increased VEGF secretion by tumor cells while interruption of the pathway significantly
reduced VEGF levels and the number of blood vessels in tumors63. Endothelial cells
have also been found to secrete higher levels of VEGF in vitro and increased tube
formation in a GCN2-dependent manner when deprived of the amino acids methionine
and cysteine in the context of hypoxia62. GCN2 has also been shown to be critical in the
immune populations of the TME. In a glioblastoma model, GCN2 was found to be critical
for tumor infiltration by cytotoxic T-cells and was also shown to be pivotal for their
survival during tryptophan deprivation.65 The ISR pathway is activated in response to
stress stimuli in fibroblasts just as in many other eukaryotic cells. Most studies have
focused on the role of the ISR in mouse embryonic fibroblasts (MEFs), while the role of
the ISR in adult stromal cells of the TME has not yet been extensively investigated.
In summary, the TME is composed of various cell types that each contribute
towards tumor progression both in concert and independent of other cellular populations.
Cells in the TME have the ability to function as both pro- and anti-tumor populations thus
it is important to understand the signaling pathways regulating these opposing actions.
For example, the immune cell population with its surveillance ability to destroy foreign
cells, also exhibits tumor promoting actions through their exhaustion, lack of efficacy,
and production of factors that alter other immune populations towards a pro-tumor
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phenotype. Endothelial cells are also subject to changes within the TME as their rapid
expansion in response to increased production of growth factors from cancer cells
prevents the development of fully functioning or mature blood vessels resulting in
inefficient vasculature. Cancer associated fibroblasts, abundant throughout the TME, are
known to promote tumor growth in part due to their increase in FAP expression which
results in fibroblast activation and the production and remodeling of ECM proteins that
promote tumor growth, migration and metastasis. While the stresses of the TME are
experienced by both tumor cells and the surrounding “normal” cells, the utilization of the
ISR pathway promotes cell survival and is an attractive therapeutic target. Thus, it is of
great interest to understand the role of the ISR in cells in the TME and in fibroblasts.
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CHAPTER 2: Tumor Suppressors and the Integrated Stress Response

Introduction
In response to amino acid deprivation (AAD), previous studies on mouse
embryonic fibroblasts (MEFs) have shown that MEFs activate the Integrated Stress
Response (ISR) pathway to cope with the lack of nutrients until the stress is alleviated.
Tumor suppressors such as the most commonly mutated tumor suppressor, p53, have
been well studied for their role in cancer cells but less is known about their role in cells in
the tumor microenvironment (TME) 66,67. Wild-type (WT) p53 typically inhibits cancer
progression through a number of different mechanisms including cell cycle arrest,
induction of apoptosis and senescence. However, mutant p53 can be pro-tumorigenic
through functions that include regulating cancer cell metabolism with gain of function
mutant p53 promoting glycolysis and lipid synthesis and tumor growth68. WT p53 has
also been shown to have pro-tumor ability in cancer cells in response to AAD. Cancer
cells with WT p53 when subjected to AAD undergo cell cycle arrest to promote their
survival through the upregulation of the p53-target gene p21; this upregulation and
overall cell survival was lost when p53 was ablated in these cells69,70. Interestingly,
upregulation of p21 in this context coincided with activation of the ISR as evidenced
through phosphorylation of eIF2a and increased transcription of genes associated with
the AAD response, including CHOP, which was reduced when p53 was mutated70. While
these studies have primarily investigated p53 and its effects in cancer cells, p53’s role in
other cell types in the TME, including stromal and endothelial cells is less well
understood.
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Genetic screening of CAFs revealed that although somatic mutations of p53 in
cancer models were rare, the potential silencing of genes by epigenetic changes in the
TME cannot be ruled out 71,72. To this end, the silencing of p53 in CAFs has been
investigated in tumor models. The effect of stromal cell-derived p53 on tumor growth has
been investigated in pancreatic and carcinoma models. These studies revealed an
increase in tumor growth when normal fibroblasts were mixed with cancer cells that was
enhanced when p53 was deleted or mutated to mimic potential epigenetic silencing73,74.
Studies show that the rate of tumor growth in flank tumor models was significantly faster
when tumor cells were co-injected with normal fibroblasts and tumor growth was further
enhanced when normal p53 was deleted, mutated or altered epigenetically. However,
this effect was abrogated when p5374 or stromal cell derived factor -1 (SDF-1)73 were
targeted in fibroblasts. These findings suggest that p53 in the stroma affects tumor
growth but the effect of p53 in stromal cells in the TME in response to stress and
activation of the ISR, has had limited investigation. In response to leucine deprivation,
MEFs with an inactive p53 mutant still showed induction of a p21 variant in a GCN2dependent manner that was utilized by cells to survive the stress of AAD75. The
depletion of p53 and its homologs, p63 and p73, did not prevent the upregulation of p21
suggesting that p53 is not required for p21 induction in MEFs under these conditions.
One potential explanation could be the ability of p53 homologs to act on the promoter
regions of p53 target genes. It has been previously shown that the p63 isoform is able to
bind the promoter region of p21 in human epidermal keratinocytes at different stages of
differentiation76. As these studies have provided a potential link between the ISR, cell
cycle arrest and p53, my studies have focused on investigating the effects of other tumor
suppressors on the ISR pathway in response to stress of the TME and particularly the
fibroblast population.
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Another tumor suppressor of interest is the P14 alternate reading frame
(P14ARF) tumor suppressor, or the mouse homolog, p19Arf. P14ARF, the second
most commonly mutated tumor suppressor in human cancers, is encoded in the
CDKN2A gene67. The role of P19Arf as a regulator of p53 activation has been well
characterized in vivo and in vitro. In normal conditions, p53 is kept at low levels as it is
targeted for lysosomal degradation via the E3 ubiquitin-protein ligase mouse double
minute 2 homolog (MDM2). However when p53 activation is required in response to a
range of cellular stresses including oncogenic stress77–79, ultra-violet or gamma
irradiation80, or hypoxia81, p19Arf expression is upregulated and activated, which results
in the binding and sequestering of MDM2, translocating it to the nucleolus permitting the
stabilization and functional activation of p53 (Figure 2.1)67,82. While this narrative
presents p19Arf as a tumor suppressor only in a p53-dependent context, it has also
been shown to function in a p53- independent manner. Mice with triple knock-out of
p19Arf, p53 and Mdm2 develop multiple tumors at a frequency greater than that
observed in mice lacking both p53 and Mdm2 or p53 alone. This data demonstrates that

Figure 2.1: p19Arf -p53 canonical pathway. Under normal conditions, p53 activity is tightly
regulated and targeted for degradation by the E3 ubiquitin ligase, MDM2. In response to
cellular insults that require p53 activation, the p19Arf tumor suppressor sequesters and
relocates MDM2 to the nucleus permitting p53 activation and function.
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p19Arf can act independently of the Mdm2-p53 axis in tumor suppression playing roles
in cell cycle arrest and senescence in tumor cells77.
P19Arf has been shown to induce cellular responses independent of p53 in
response to oncogenic stimuli including anti-tumorigenic functions such as apoptosis,
cell cycle arrest, and senescence. P19Arf can also induce these functions in normal
MEFs. Weber et al., showed that when p19Arf was reintroduced into MEFs lacking p53,
MDM2, and p19Arf, these cells displayed an ability to induce cell cycle arrest that was
independent of the p53 target gene p2183. p14ARF has also been shown to induce cell
death independent of p53 in human cancer cells. When P14ARF was transfected into
p53-deficient human carcinoma cells, not only was there a reduction in viable cell
number and an increase in apoptosis markers in vitro, but this was also recapitulated in
vivo as harvested tumors revealed a reduction in proliferating cells and an increase in
cleaved caspase-384,85. While apoptosis and cell cycle arrest are critical for tumor
suppression, senescence is another cellular response that is associated with reduced
tumor progression. The p19Arf tumor suppressor is required to induce senescence in
response to stress as it works in concert with the tumor suppressors Ink4a or p1685–87. In
addition, p19Arf can also induce autophagy as another cell survival mechanism that has
been viewed as double-edged sword in cancer for its ability to not only induce apoptosis
as a tumor suppressive response but also its utilization by cancer cells to maintain
sufficient nutrients for tumor progression in certain models88. Previous studies have
shown that a small mitochondrial isoform of p19Arf (smARF) induces autophagy and
apoptosis in a p53-dependent manner in both fibroblasts and cancer cells85,89. It has also
been shown to promote tumor progression by promoting autophagy during nutrient
deprivation in lymphomas85,90. While these studies have shown the involvement of
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p19Arf in cellular responses, limited investigation has connected the ISR and the p19Arf
tumor suppressor. One study showed the ability of ATF4 to suppress p19Arf allowing
transformed cells to maintain plasticity and colony formation ability, that was lost when
Atf4 was deleted7. Due to the gap in knowledge regarding the link between p19Arf and
the ISR, my work has been investigating the role of p19Arf in stromal cells and its effect
on the ISR in response to stress in the TME.
As the loss of p19Arf in mouse models of cancer has been shown to promote
tumor growth and its loss in MEFs leads to immortalization, I hypothesized that the loss
of p19Arf in the TME enhances tumor growth through increased activation of fibroblasts.
My data demonstrates that in addition to increased tumor growth in a p19Arf-null mouse
host, primary p19Arf-null fibroblasts co-injected with cancer cells showed an increased
rate of tumor growth. My data also shows that growth of 3-dimensional (3D) tumor
organoids or tumoroids, formed in the context of a fibroblast network was enhanced
when co-cultured with p19Arf-null fibroblasts. My data also shows that fibroblasts
upregulate expression of the p19Arf tumor suppressor in response to prolonged leucine
deprivation. Our data indicate a role for p19Arf in fibroblasts to slow tumor growth in
mice and ex vivo 3D tumoroid development, in addition to our finding that P19Arf is
upregulated in response to prolonged leucine deprivation in primary fibroblasts.

Results
Loss of p19Arf in the microenvironment increases tumor growth
To investigate the role of P19Arf in the TME, WT or p19Arf-/- mice were inoculated
with syngeneic murine sarcoma (SKPY) or Lewis lung carcinoma cells (LLC) in the flank
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and tumor growth was monitored over time. The rate of tumor growth was increased in
p19Arf-/- mice indicating a role for P19Arf in the tumor microenvironment (Figure 2.2A). To
assess the tumor promoting capabilities of p19Arf-/- adult lung fibroblasts (ALFs), we
generated 3D tumoroids with WT or p19Arf-null ALFs to more closely recapitulate in vivo
tumor growth and to specifically examine the effect of ALFs on tumor growth. WT or
p19Arf-/- ALFs were seeded in basement membrane extract. Lewis lung carcinoma (LLC)
cells were plated on top of the solidified basement membrane and formed 3D tumors. We
show that LLC tumoroids with fibroblasts show an increase in tumor cell numbers as
compared to growth of LLCs alone, and this phenotype is further enhanced when
fibroblasts with deletion of p19Arf were utilized. This increase in tumor cell proliferation in
3D tumoroids was also observed with p19Arf-null fibroblasts during long-term leucine
deprivation (Figure 2.2B). To investigate whether cancer cells within the tumoroids
promoted fibroblast activation, tumoroids were digested into single cell suspensions and
cells were mounted and stained for proliferation and fibroblast activation using Ki67 and
α-smooth muscle actin (SMA), respectively. My data shows actively proliferating fibroblast
populations within the tumoroid as evidenced by nuclear Ki67 staining and α-SMA
expression that is increased in p19Arf -/- fibroblasts (Figure 2.2C,D,E). These data suggest
that loss of p19Arf in fibroblasts, promotes tumor cell growth in 3D tumoroid assays and
demonstrates cross-talk between tumor cells and fibroblasts. These data further support
the notion that P19Arf functions as a tumor suppressor in fibroblasts in the TME.
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Figure 2.2: Loss of p19Arf in fibroblasts promotes tumor growth. A. Graph of sarcoma
(SKPY) and Lewis lung carcinoma (LLC) tumor volume on the indicated days. SKPY or LLC
cells were injected into the flank of WT and p19Arf-null mice. Tumor volume was measured
by caliper. N=7-15 mice/cohort B. Representative images of tumoroids containing LLC cells
with either WT or p19Arf -/- fibroblasts after 5 days of co-culture in basement membrane
extract. Bars are 250µm. Quantification of cell counts are shown in graph on right. Yellow
arrows = fibroblast network; black arrows = tumoroid. C,D,E. Representative images of
dissociated cells from tumoroids stained for (C) Ki67, (D) a-SMA, and (E) both Ki67 and aSMA. Quantification is shown on the right. Bars = 50µm. n = 5. *p<0.05.

P19Arf is induced in response to amino acid deprivation and activates the Integrated
Stress Response pathway
P19Arf is known to be induced in response to oncogenic stress and DNA damage,
stabilizing and activating p5367,78,79. TP53 has also been shown to be upregulated during
AAD in breast cancer cells, but the effect of AAD on P19Arf expression and function has
not yet been investigated91. To cope with AAD, cells activate the ISR exclusively through
the GCN2 arm of the pathway resulting in phosphorylation of eIF2a (p-eIF2a) and nuclear
localization of ATF454. We probed for activation of the ISR in WT and p19Arf

-/-

ALFs in

response to prolonged leucine deprivation with our data showing increased p-eIF2a in WT
fibroblasts that was even further increased in p19Arf-/- fibroblasts confirming ISR pathway
activation in both WT and p19Arf-null fibroblasts (Figure 2.3A). Activation of the ISR
occurs through many different stimuli. To confirm dependence on GCN2 activity in
response to AAD, we treated cells with a GCN2 inhibitor (GCN2-IN-1)92 and probed for peIF2a in response to leucine deprivation. We show increased phosphorylation of eIF2a
in p19Arf-/- fibroblasts, which is ablated when cells were treated with GCN2-IN-1 during
leucine deprivation confirming increased GCN2 activation in response to the amino acid
deprivation in p19Arf-/- ALFs (Figure 2.3B).Exposure of WT ALFs to leucine deprivation
revealed upregulation of p19Arf expression at the mRNA and protein level after 24 hours
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that was sustained over 3 days (Figure 2.3C,D). In addition to overall expression levels
of p19Arf, it’s localization within the cell is also indicative of its activity93. In response to
leucine deprivation, we show that nuclear localization of P19Arf increases when leucine
deprivation is prolonged (Figure 2.3E). These findings suggest that p19Arf induction in
response to prolonged leucine deprivation contributes to activation of the ISR pathway in
primary fibroblasts.
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Figure 2.3: Leucine deprivation (LD) induces p19Arf expression in primary murine adult
lung fibroblasts (ALF) and activates the integrate stress response pathway. A. Western blot
analysis of phospho-eIF2a and total eIF2a expression in wild-type (WT) and p19Arf-null
murine ALFs during LD for the indicated days. Graph quantifies intensity of phospho-eIF2a
expression relative to Day 0. β-Tubulin used as loading control. B. Western blot analysis of
phospho-eIF2 expression in WT and p19Arf-/- ALFs upon treatment with a GCN2 inhibitor
(GCN2-IN-1; A-92 1µM in DMSO) during overnight LD. Actin used as a loading control.
Quantification of phospho-eIF2 expression relative to total eIF2a. N=3. C. qPCR for p19Arf
mRNA in WT or p19Arf-/- fibroblasts during LD for the indicated days. D. Western blot for
p19Arf protein expression in WT and Arf-null fibroblasts after LD for the indicated days. E.
Representative immunofluorescence images for P19Arf subcellular localization on the indicated
days after LD in WT or p19Arf-/- ALFs. Quantification of nuclear p19Arf is shown in graph on
right.

Discussion
During tumor progression, the TME plays a pivotal role in the maintenance and
growth of the primary tumor and metastasis of cancer cells. Of the populations that
constitute the TME, stromal cells play critical roles in promoting tumor growth and
metastatic progression. Tumor cells are thought to activate normal cells such as
fibroblasts, in their local microenvironment leading to remodeling of matrix and creating a
favorable niche for tumor growth. Although fibroblasts in the TME are thought to be
genetically stable, emerging data suggests that epigenetic regulation of gene expression
in ‘normal’ cells in the TME may play important roles in tumorigenesis. Thus studies
investigating how loss of tumor suppressor genes such as p53 or p19Arf affects fibroblast
function in the TME may offer insight into the role of tumor suppressors in cancer
associated fibroblasts (CAFs)74. In this study, we investigated the role of the second most
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commonly mutated tumor suppressor, p19Arf, in adult lung fibroblasts Here we show that
p19Arf is induced in fibroblasts in response to AAD, a common stress in the TME. While
the p19Arf tumor suppressor has been shown to be induced in response to hypoxia and
DNA damage, its induction in response to leucine deprivation has not yet been
demonstrated.
Although our work did not investigate P53-independent functions of p19Arf in
fibroblasts, its role in senescence, ribosome biogenesis, and SUMOylation has been well
established with p19Arf expression a commonly used marker of senescence. It has also
been suggested that increased ribosome biogenesis is a common hallmark of cancer that
provides a potentially actionable target for cancer treatment94. Many different types of
autophagy have been identified including mitochondrial autophagy (mitophagy) and
ribosomal autophagy (ribophagy). Considering p19Arf’s role in regulating ribosome
biogenesis and autophagy, it would of interest to investigate p19Arf’s tumor suppressive
role through ribophagy.
A known regulator of autophagy is the mTOR pathway which primarily regulates
cell proliferation and is dependent on the availability of nutrients. In normal conditions, the
mTOR pathway, specifically mTOR complex I (mTORC1) regulates mRNA translation,
protein turnover, and cellular metabolism. The mTOR pathway is manipulated in cancer,
and components of the pathway have been shown to degrade p19Arf to promote
proliferation in MEFs95. Further studies will investigate the effect p19Arf loss on the mTOR
pathway and its regulation on cell processes including proliferation, metabolism, mRNA
translation, and protein turnover.
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The loss or mutation of the human p14Arf tumor suppressor in cancer cells has
been identified in numerous cancer types. However, the role of the p14Arf tumor
suppressor in the TME has not been investigated and could offer a promising area of
investigation to enhance existing therapies. Collectively, our data demonstrate a role for
p19Arf in fibroblast activation and its loss promotes fibroblast survival and activation during
nutrient deprivation leading to a pro-tumorigenic phenotype in primary lung fibroblasts and
increased tumor growth. Further elucidation of the specific downstream targets of p19Arf
in primary lung fibroblasts will provide insight into the link between loss of p19Arf and
activation of autophagy during nutrient deprivation and may provide new pharmacological
targets in the stroma.
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CHAPTER 3: p19Arf Loss Enhances Fibroblast Survival and Function During
Prolonged Leucine Deprivation

Introduction
We have shown in Chapter 2 that the loss of p19Arf in the tumor microenvironment
(TME) enhances tumor growth rates in murine models. This was also recapitulated in 3D
tumoroid colonies when primary fibroblasts are the only other cell type in the local
environment. We also showed that the loss of p19Arf in these fibroblasts not only promotes
tumor cell proliferation in both normal conditions and leucine deprivation (LD), but also
increases fibroblast numbers suggesting bi-directional cross-talk between tumor cells and
fibroblasts. We investigated the role of p19Arf in these fibroblasts and showed induction
of p19Arf at both the mRNA and protein levels in response to prolonged LD. Increased
P19Arf expression also coincided with activation of the ISR pathway and was further
enhanced when p19Arf was deleted in these fibroblasts. This suggests that the loss of
p19Arf enhances fibroblast activation and promotes their stability in response to stresses
of the TME. To this end, we investigated the function of p19Arf in primary adult fibroblasts
to determine the survival mechanisms utilized during long-term amino acid deprivation
(AAD) upon p19Arf loss. Other studies have investigated the role of p19Arf in fibroblasts
in diseases other than cancer. In aging related studies, p19Arf and p14ARF are commonly
upregulated and required to induce senescence of late passage cells86,96. P19Arf ablation
in cells revealed the onset of age-related pulmonary fibrosis and enhanced pulmonary
function in mice suggesting that p19Arf plays a role in fibroblast function in benign
disease97. Fibroblast migration has also been shown to require p19Arf as Guo et al.,
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showed a decrease in fibroblast motility when p19Arf was deleted that was rescued when
p19Arf was reintroduced98. In addition to fibroblast motility, the ability of fibroblasts to
invade through basement membrane is also a hallmark of cancer that is associated with
metastasis and poor tumor prognosis99. In cancer cells, p19Arf inhibits invasion through
basement membrane in a p53-independent manner100. While these studies have indicated
a role for p19Arf in fibroblast function and cancer cell invasion in normal conditions, it begs
the question of whether stress in the TME alter these functions, and the contribution of
fibroblast-derived p19Arf.
The role of p19Arf has been implicated in various fibroblast functions and activation
thus I hypothesized that the increased activation of p19Arf-null fibroblasts was due in part
to increased proliferation requiring autophagy for survival during prolonged LD. Our study
has revealed that the increased proliferation of p19Arf-null fibroblasts observed under
normal conditions permits increased survival in response to the deprivation of the essential
amino acid, leucine, that is lost when proliferation of p19Arf-null fibroblasts is inhibited.
We also show increased activation of p19Arf-null fibroblasts as observed through
increased migratory and invasive abilities even during prolonged LD. Finally, we show a
dependence and utilization of autophagy pathways in p19Arf-null fibroblasts that promote
cell survival even at baseline but is further upregulated in response to prolonged LD.
Pharmacological inhibition of autophagy attenuates the survival response of p19Arf-null
fibroblasts during long-term LD indicating the necessity of this pathway for survival.
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Results
Loss of p19Arf promotes fibroblast survival during leucine deprivation
There is little understanding of how cells in the tumor microenvironment respond
to chronic stress during tumorigenesis such as AAD. In response to sustained AAD over
days, we show that WT ALFs eventually die in contrast to p19Arf-/- fibroblasts that continue
to proliferate even during long-term LD (Figure 3.1A). The loss of p19Arf in mouse
embryonic fibroblasts (MEFs) increases proliferation due in part to the loss of p53 function
and loss of cell cycle checkpoints67,83. p19Arf deletion enhances ALF survival during AAD
that is due in part to the increased proliferation of p19Arf-null ALFs relative to WT ALFs.
EdU uptake confirms the increased proliferation of p19Arf-/- ALFs as compared to WT
fibroblasts during long-term AAD (Figure 3.1B). To determine whether increased survival
of p19Arf-/- ALFs was due to increased proliferation, we treated fibroblasts with mitomycin
C to inhibit DNA synthesis (Figure 3.1C) and exposed ALFs to long-term LD. Mitomycin
C treated ALFs exposed to AAD revealed that p19Arf-/- ALFs die during long-term leucine
deprivation similar to WT ALFs suggesting that survival of p19Arf-null fibroblasts may be
dependent primarily on their increased rates of proliferation (Figure 3.1C). P19Arf
activation is necessary to induce apoptosis in a p53-dependent manner101,102. To assess
whether deletion of p19Arf in ALFs reduced apoptosis, fibroblasts were stained with
Annexin V after AAD. Our data show similar levels of Annexin V staining between LD WT
and p19Arf

-/-

ALFs indicating apoptosis in response to AAD was unaffected by p19Arf

status (Figure 3.1D). These data suggest that the loss of Arf enhances ALF proliferation
and survival during AAD promoting tumor progression.
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Figure 3.1: Loss of p19Arf enhances fibroblast proliferation during leucine
deprivation (LD). A. Quantification of trypan blue negative WT or p19Arf -/- lung
fibroblasts on the days indicated after normal (left graph) media or LD-deprived (right
graph) media. Fold change is relative to Day 0 cell counts. B. Representative images of
EdU uptake (16-hour pulse) of WT or p19Arf -/ -lung fibroblasts after LD for the
indicated days. Bar = 50µm, n=3, * p<. C. Representative images of EdU uptake of WT
or p19Arf -/- lung fibroblasts during LD and treatment with mitomycin C (Mito C) and
graph of viable cell numbers. Fold change is relative to Day 0.
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P19Arf -/- fibroblasts show increased activation during leucine deprivation
Fibroblast activation and migration in response to injury can be modeled in a
scratch assay. ALFs are seeded in tissue culture dishes and grown to confluency then
denuded with a pipet tip. We show that p19Arf-/- fibroblasts migrate more rapidly than WT
fibroblasts covering the denuded area in the presence of LD media faster than WT
fibroblasts (Figure 3.2A). Similarly p19Arf-/- ALFs migrated more rapidly through a
transwell in response to serum in LD conditions further indicating that loss of p19Arf
enhances fibroblast activation (Figure 3.2B). When cancer associated fibroblasts are
activated, they migrate through collagen and other extracellular matrix in the tumor
microenvironment by cleaving and reorganizing matrix. Invasion assays with ALFs through
a collagen bed revealed increased invasion by p19Arf-/- ALFs, that was maintained during
LD suggesting more active fibroblasts and an ability to more rapidly modify collagen
(Figure 3.2C). In collagen remodeling, ALFs both degrade and deposit collagen providing
an opportunity to investigate the role of p19Arf in collagen deposition by primary
fibroblasts. Quantification of hydroxyproline serves as a surrogate for collagen production
as hydroxyproline is a major component of collagen. Utilizing supernatant collected from
fibroblasts during collagen invasion assays, hydroxyproline levels were measured
revealing a surprising reduction in collagen production by p19Arf

-/-

ALFs both in normal

media and during LD. This data suggests that either collagen production is decreased in
the absence of P19Arf or that the loss of p19Arf- in ALFs increases collagen degradation,
but not collagen deposition in response to AAD (Figure 3.2D). Overall, these results
suggest the loss of p19Arf increases fibroblast activity during LD that could enhance tumor
progression.
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Figure 3.2: Loss of p19Arf enhances fibroblast activation during leucine deprivation
(LD). A. Representative images and quantification of scratch closure by WT or p19Arf-/fibroblasts in the presence of complete or LD media. Scratch closure rate was calculated at
the indicated times relative to 0 hr. Bar = 250µm, n= 3, * p< 0.05, ** p<0.01. B.
Representative images and quantification of fibroblast transwell migration. WT or p19Arf /fibroblasts were placed in serum-free media with or without LD in the top chamber of
transwells and migrated toward complete serum-containing media in lower chamber.
Migration was assessed after 24 hours by staining with crystal violet. Quantification of
migrated cells per high powered field (hpf) is on right. Bar = 100µm, n=3, p<0.01. C.
Representative images and quantification of collagen invasion assays. Fibroblast in serumfree normal or leucine free media were placed in the top chamber of transwells coated with
type 1 rat tail collagen bed and invaded through the collagen bed and migrate toward
complete serum-containing media in lower chamber. Invasion was assessed after 72 hours
by staining with crystal violet. Bar = 100µm, n=3. D. Quantification of hydroxyproline
levels in conditioned media of WT and p19Arf -/- fibroblasts during collagen invasion
assays in serum-free media with or without LD.

Loss of p19Arf increases autophagic flux in primary fibroblasts during LD
Increased proliferation and long-term survival of p19Arf-null fibroblasts during LD
implicates autophagy as a mechanism by which p19Arf-/- ALFs survive in the absence of
the essential amino acid leucine. Previous studies have shown that in response to AAD,
cells induce autophagy to recycle organelles and obtain nutrients required for survival. To
investigate autophagic flux in WT and p19Arf-/- ALFs during LD, we examined expression
of the p62 cargo receptor protein, and the dynamic processing of microtubule-associated
proteins 1A/1B light chain 3B (LC3) from LC3-I to LC3-II by Western blot. We show
increased p62 expression in p19Arf-null ALFs during prolonged AAD as compared to WT
ALFs (Figure 3.3A). Similarly, we find an increase in LC3-II levels during AAD in p19Arfnull ALFs at both baseline and in response to AAD (Figure 3.3B). Collectively these data
suggest increased autophagy during LD in p19Arf null fibroblast promoting ALF survival.
Treatment of ALFs with bafilomycin, a drug that raises the pH of the autophagolysosome
to inhibit autophagy, showed an increase in LC3-II levels during leucine deprivation
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confirming the induction of autophagy (Figure 3.3B). To determine the effect of autophagy
on ALF survival, cells were subjected to LD and additionally treated with the autophagy
inhibitors bafilomycin or hydroxychloroquine. We show that the survival benefit of p19Arf/-

ALFs during LD is lost when autophagy is inhibited with either chloroquine (Figure 3.3C)

or bafilomycin (Figure 3.3D) resulting in decreased ALF survival. These data confirm that
p19Arf -/-ALF are dependent on autophagy to promote their survival during long-term LD
through enhanced autophagic flux.
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Figure 3.3: Loss of p19Arf increases autophagy in primary fibroblasts during
leucine deprivation (LD). A, B. Western blot analysis of autophagy markers (A) p62
and (B) LC3-I to LC-3II conversion in WT and p19Arf-/- fibroblasts during LD for the
indicated days. C, D. Fibroblast cell numbers in the presence of the autophagy
inhibitors (C) chloroquine [100nM] or (D) bafilomycin [1nM] during LD for the
indicated days. n=3, * p<0.05, ** p<0.01, *** p<0.001.

40

Discussion
My data demonstrate that the increased proliferation of p19Arf -/- fibroblasts offer a
survival advantage over WT fibroblasts in response to prolonged AAD. In support of this,
I show that survival of p19Arf-/- ALFs during long-term LD is lost in the presence of the
DNA synthesis inhibitor, mitomycin C indicating that increased proliferation is a critical
mechanism for survival during LD. Our data also show increased migration of p19Arf-null
fibroblasts during LD in scratch assays, through transwells and through a collagen bed
suggesting that p19Arf-/- ALFs have the ability to promote tumor growth in the TME with
limited nutrients.
In response to nutrient deprivation, cells recycle existing cellular components to be
used as nutrients to promote survival, a process known as autophagy. Cancer cells often
use this mechanism for survival in the nutrient deprived TME, but increased autophagy
has also been shown to inhibit tumor growth. We show here that autophagy is increased
in p19Arf-null ALFs as compared to WT ALFs during LD as evidenced by the conversion
of LC3-I to LC3-II and the degradation of p62. Interestingly, we find that p19Arf-/- fibroblasts
at baseline contain higher levels of p62 and LC3-II that were even further upregulated
when autophagy was inhibited, suggesting p19Arf-/- fibroblasts enhance autophagy to
promote their survival. Using two well characterized autophagy inhibitors bafilomycin and
hydroxychloroquine, I confirmed the importance of autophagy for survival of p19Arf-null
fibroblasts during prolonged LD. The decreased survival of p19Arf-null ALFs during LD in
the presence of bafilomycin or hydroxychloroquine confirms the necessity of autophagy to
promote survival under nutrient deprivation conditions. Further studies will be needed to
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determine how p19Arf may directly or indirectly regulate autophagy to inhibit fibroblast
survival under conditions of nutrient deprivation. Previous studies have shown that
inhibition of autophagy in vivo slows tumor growth rates and inhibits tumor progression. It
will be of interest to investigate whether restriction of an essential amino acid through diet
could improve autophagy-based cancer therapies.
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CHAPTER 4: Shear Stress and its Effect on the Tumor Microenvironment
Introduction
In addition to stresses of the tumor microenvironment (TME) associated with the
lack of resources due to a rapidly expanding tumor mass, there are other stresses
induced by biophysical stimuli such as blood flow resulting in shear stress. Shear stress
is defined as the measure of the force of friction from a fluid acting on a body in the path
of that fluid103. The endothelial cell monolayer lining blood vessels throughout the body
are directly exposed to the shear stress of blood flow. While physiologic shear stress is
necessary for normal vascular function, aberrant or pathologic changes that disturb
shear stress or cause oscillatory flow can activate endothelial cells altering their
behavior104. Studies have shown that these changes can be associated with plaque
deposits, atheroma formation and atherosclerotic disease103. Altered vascular flow
affects the vascular endothelium at the cellular and molecular level changing gene
expression, cytoskeletal rearrangement, and leukocyte adhesion among other things.
These changes together with well-defined risk factors including obesity, smoking and
hypertension lead to atherosclerosis, a chronic disease with plaque buildup in arteries
restricting blood flow that can result in occlusion of the artery if the plaque ruptures105.
Studies have shown that similar molecular pathways in endothelial cells play a role in the
progression of both atherosclerosis and cancer105. In cancer, shear stress has been
implicated as having both tumor promoting and suppressive abilities. Tumor cells are
most likely to encounter shear stress during metastatic progression as they travel from
the primary tumor to a distal metastatic organ site and are referred to as circulating
tumor cells or CTCs. Studies show that CTCs are exposed to variable levels of shear
stress during metastatic progression that can promote its proliferation and extravasation
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. In contrast, increased shear stress has also been shown to reduce the number of

viable CTCs in various tumor models110–112. Although pathologic stimuli can trigger
increased shear stress, physiological methods such as aerobic exercise can also
increase shear stress by increasing blood flow.
Shear stress induced by moderate exercise is an important mechanism to
improve vascular function by stimulating activation of endothelial cells. As tumor
vasculature have poor endothelial function leading to leaky vessels, numerous studies
have investigated the effects of normalizing tumor vasculature to improve drug delivery
in cancer. As briefly mentioned in Chapter 1, the concept of tumor vascular
normalization can be observed with the use of antiangiogenic treatments to restore the
balance of pro- and antiangiogenic factors in the TME that leads to restoration of
abnormal tumor vasculature towards a more normal state with improved tumor blood
flow and increased oxygenation113. Tumor vascular normalization as a therapeutic
strategy to increase drug delivery have generally utilized antiangiogenic treatments to
promote normalization. These therapies lower the levels of pro-angiogenic factors such
as VEGF, to attenuate the rapid growth and proliferation of endothelial cells leading to
‘pruning’ of the excess endothelial cells causing vascular regression and a more normal
vascular bed33,114. However, the use of antiangiogenic agents not only has a limited
window for vascular normalization but is also accompanied by a number of adverse side
effects115. A physiologic approach to increasing shear stress and activating endothelial
cells is through aerobic exercise. We previously published that tumor bearing-mice
subjected to increased shear stress via treadmill running during chemotherapy showed
normalization of tumor vasculature as evidenced by an increase in mature lumens that
were more effective in perfusion and circulation of drugs to the tumor bed25. This study
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also revealed the importance of the calcineurin - nuclear factor of activated T-cells
(NFAT) - thrombospondin -1 (TSP-1) pathway in mediating vascular normalization116.
More recently, another study demonstrated that TSP1 expression may serve as a
biomarker of tumor vasculature normalization25,117. While these studies investigated the
effects of chronic exercise on increasing chemotherapeutic efficacy, the effects of acute
exercise on enhancing drug delivery and efficacy have not been investigated.
Aerobic exercise interventions can either be chronic, defined as repeated periods
of short or longer term exercise, or acute, defined as a single bout of exercise. Based
upon the effect of chronic exercise on tumor vascular normalization and increased
chemotherapeutic efficacy, I hypothesized that a single session of acute aerobic
exercise would not provide sufficient levels of shear stress to activate and remodel
vasculature. In our previous study, we showed that chronic exercise not only induced
TSP-1 and endothelial nitric oxide synthase (eNOS) expression in the lungs but we also
showed that TSP-1 expression was increased in the heart and spleen of these animals.
These data confirm increased shear stress throughout the animal. My studies
investigating the effect of acute exercise on tumor growth found that administration of
drug immediately after a session of acute aerobic exercise, showed a modest
suppression of tumor growth as compared to mice treated with drug alone.
Exercise induces adaptations in skeletal muscle through activation of the
transcriptional co-activator peroxisome proliferator-activated receptor (PPAR) family of
proteins with peroxisome proliferator-activated receptor gamma coactivator 1 alpha
(PGC1- α) one of the best characterized family member118. PGC1- α functions in
regulating mitochondrial biogenesis and oxidative metabolism and has been studied in a
number of disease states including cancer. PGC1- α has been implicated across various
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cancer types with increased expression in breast cancer associated with an increase in
mitochondrial restoration and metastasis to the bone and lung118,119. It has also been
shown to be necessary for drug resistance in colorectal cancer120. PGC1- α works in
concert with the p53 tumor suppressor in promoting cancer cell survival through cell
cycle arrest, which was lost when PGC1- α was deleted or the stress was prolonged121.
Since PGC1-α is essential for exercise-induced upregulation of skeletal muscle VEGF,
we were interested in exploring whether this factor effected exercise-induced tumor
vascular normalization in our model system. I hypothesized that increased PGC1- α
expression in the skeletal muscles of exercised mice would increase VEGF levels
systemically leading to more rapid tumor progression and metastasis to the lungs.
Utilizing PGC1- α transgenic mice generated by Arany et al.122 with overexpression of
PGC1- α in the skeletal muscles, I subjected mice to chronic aerobic exercise and
observed no difference in the growth rates between control and transgenic mice. Using
an experimental model of spontaneous lung metastases, I examined the incidence of
lung metastasis in PGC1- α transgenic mice and littermate control mice after chronic
exercise. My data show no significant difference in lung metastases between exercised
control versus transgenic mice. However, my studies do show that chronic aerobic
exercise increased metastatic burden in both PGC1- α transgenic and control mice as
compared to non-exercised transgenic or control mice suggesting that long-term
exercise in the absence of chemotherapy may promote tumor progression.

46

Results
Acute exercise increases chemotherapeutic efficacy attenuating tumor growth
As shown previously, chronic exercise in tumor bearing mice enhances
chemotherapeutic efficacy through the normalization of tumor vasculature through a
cellular mechanism that include activation of TSP-1 and the calcineurin-NFAT pathway
in endothelial cells. Since the ability of cancer patients undergoing chemotherapy to
maintain a regular exercise program may be limited, we sought to determine if acute
aerobic exercise or a single exercise training session would be sufficient to normalize
tumor vasculature and increase the efficacy of chemotherapy. Utilizing a murine
melanoma xenograft model in syngeneic wild-type (WT) mice, I inoculated mice with
melanoma cells and when tumors reached 100 mm3 in volume, mice were treated with
Doxorubicin (Dox). The sedentary group were returned to their cages and the
experimental group ran on a treadmill for one hour at a moderate intensity of VO2 as
previously described25,123. These studies showed that acute exercise offered no
increased efficacy of Dox treatment as tumors continued to grow even more rapidly in
the exercised cohort as compared to the sedentary cohort (Figure 4.1A).
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Figure 4.1: Acute exercise has no effect on tumor growth when drug is administered
before exercise. A. Graph of melanoma (B16F10) tumor volume on indicated days. B16F10
cells were injected into the flank of wild-type (WT) mice. Tumor volume was measured by
caliper, N=8 (4 sedentary, 4 exercise) mice/cohort. Doxorubicin (Dox) was administered to
both groups [2mg/kg] when tumor volume was ~100mm3 on Day 11, before the exercise
group ran on the treadmill for 60 minutes at a rate of 12 m/min. B. Graph of B16F10 tumor
volume when Dox was administered after running. WT mice receive B16F10 cells to their
flank and were allowed to grow until the previously mentioned volume was obtained at
which time exercise was performed and mice received Dox immediately after. C. Graph of
pancreatic adenocarcinoma (PDAC) tumor volume when Dox is administered before and
after running. WT mice were inoculated with syngeneic PDAC cells in their flank and
received Gemcitabine (Gem) [15mg/kg] before or after acute exercise. Tumor volume was
measured by caliper. N= 11 (3 sedentary, 4 with Gem before exercise, 4 with Gem after
exercise) mice/cohort.

One possible explanation for this increase in tumor growth after an acute exercise
intervention in the presence of Dox was that the clearance of Dox occurred more rapidly
upon the increase in blood flow from acute aerobic exercise. Next I examined the effect
of Dox treatment within 15 minutes after completion of acute aerobic exercise in
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melanoma-bearing mice and found that tumor growth was inhibited when chemotherapy
was administered after treadmill running as compared to the non-exercised melanomabearing cohort (Figure 4.1B). However, when these studies were repeated utilizing a
xenograft model of pancreatic ductal adenocarcinoma (PDAC), the administration of
Gemcitabine (Gem) either before or after running had no effect on tumor growth (Figure
4.1C). These data indicate that chemotherapy administered after acute exercise may
attenuate tumor growth only in specific cancer types. Further, I propose that the
increased efficacy of Dox treatment after acute aerobic exercise may be due to the
transient increase in shear stress permitting more efficient drug delivery to the tumor.

PGC1- α has no effect on metastatic burden in the lungs after exercise
I next examined how chronic aerobic exercise would effect tumor progression in
transgenic mice with PGC1- α overexpression124. PGC1- α transgenic mice and
littermate controls were inoculated with syngeneic Lewis lung carcinoma (LLC) cells into
their flank and tumors were monitored for growth up to a volume of ~500mm3. The
growth rate of flank tumors were similar between transgenic and control mice (Figure
4.2A). Utilizing an experimental model of spontaneous lung metastases referred to as
the injection/resection model125, I resected flank tumors when they reached 500 mm3
then both cohorts of mice (PGC1- α transgenic mice and littermate controls) were
subjected to chronic aerobic exercise for two weeks at 12 meters per minute for 45
minutes per day and five days a week prior to examining lungs for metastatic disease.
After two weeks, mice were euthanized and lungs were harvested, fixed, paraffin
embedded and sectioned. Lung sections were stained with hematoxylin and eosin to
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identify metastatic lesions but revealed no difference in metastatic incidence, or size of
metastatic lesions between the transgenic and control mice cohorts (Figure 4.2B).
These data suggest that overexpression of PGC1-α in skeletal muscle has no effect on
tumor growth and metastasis and that chronic aerobic exercise had no impact on
metastatic progression.

Figure 4.2 Transgenic mice with overexpression of PGC1-α in skeletal muscle showed no
difference in lung metastasis as compared to control mice metastasis after chronic
aerobic exercise. A. Graph of Lewis lung carcinoma (LLC) flank tumor volume on indicated
days. LLC cells were injected into the flank of WT and PGC1- α transgenic mice. Tumor
volume was measured by caliper. N=8 (4 sedentary, 4 exercise) mice/cohort. Tumors were
resected when tumor volumes were ~500-800mm3. After three days of exercise training, ,
mice were subjected to chronic aerobic exercise 5 times a week at 12m/min for 45 minutes
for two weeks at which point lungs were harvested and formalin fixed, paraffin embedded
and sectioned. B. Representative images of lung sections from exercised mice stained with
H&E. Bar = 50 pixels. Quantification of lung metastases per mouse and average size of lung
metastases is shown below. Size of lung metastases was normalized to total lung area. N=27
(6 WT sedentary, 7 WT exercise, 7 PGC1-α sedentary, 7 PGC1-α exercise).
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Discussion
My data reveal that the timing of chemotherapy delivery relative to a single bout
of acute aerobic exercise is critical to inhibit tumor growth. I showed that tumor growth
was attenuated only when Dox was administered immediately after acute aerobic
exercise but not before acute exercise. It is possible that the delivery of Dox immediately
after acute exercise may be more efficient due to the increased shear stress as a result
of aerobic exercise. We have previously shown that when a bolus of Dox was
administered before exercise, there was no difference in the amount of drug within the
tumor between sedentary and exercised groups25. In this current study, I also examined
the effect of transgenic overexpression of PGC1-α in muscles fibers on tumor growth
and metastatic progression and found no effect on the growth of primary flank tumors as
compared to control mice. Similarly, upon investigation of the effect of chronic aerobic
exercise on metastatic progression in PGC1-α transgenic mice, I also found no
significant difference in metastatic incidence or burden in exercised transgenic versus
control mouse cohorts. However, metastatic burden was increased in exercised PGC1-α
and exercised control mice as compared to their sedentary counterparts.
My data suggests an additional method to enhance delivery of chemotherapy
immediately after an increase in shear stress. Further, our acute exercise regimen in
mice would be roughly equivalent to brisk walking on an inclined treadmill for humans, a
potentially feasible intervention for cancer patients. It would be of interest to investigate
the activation of the calcineurin-NFAT pathway by examining TSP-1 levels in response
to acute exercise. While TSP-1 has been implicated in tumor vascular normalization and
angiogenesis associated with chronic exercise, it may be altered in acute exercise or
may be effected in response to Dox treatment. In addition to the calcineurin pathway and
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its activation in response to changes in calcium levels as a consequence of VEGFmediated activation of endothelial cells, it would also be of interest to investigate the ISR
pathway with particular interest in the PERK arm as changes in calcium levels also
induces stress in the endoplasmic reticulum. Our studies investigating the role of PGC1α in tumor progression showed no significant effect of PGC1- α overexpression on
tumorigenesis. However, the LLC tumor cells utilized in these mice are an aggressive
and rapidly growing tumor line and more subtle effects of PGC1- α overexpression may
be lost. Studies should be repeated with an alternate, slower growing tumor model and
VEGF levels should be measured in tumor bearing-transgenic mice with and without
chronic exercise to determine how VEGF levels are effected. Another limitation to these
studies is the fact that transgenic expression of PGC1- α was limited to type-II skeletal
muscle fibers, it would be of interest to determine the effects on tumorigenesis if the
PGC1-α transgene was conditionally activated in various cell types in the TME such as
fibroblasts or endothelial cells or in distal organs that are common sites of metastasis
such as the lungs and liver.
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CHAPTER 5: Conclusions and Future Directions

Collectively, my thesis work has investigated the role of fibroblasts and
endothelial cells in the tumor microenvironment (TME) in response to stress. My studies
on fibroblasts demonstrate a role for the p19Arf tumor suppressor in fibroblasts in
response to stresses of the TME. The loss of p19Arf in fibroblasts resulted in the
increased activity and survival of primary lung fibroblasts during prolonged leucine
deprivation (LD). Previous tumor studies have shown that p19Arf is typically inactivated
in a reciprocal manner to p53, however, studies have also shown p53-independent
functions of p19Arf. While p19Arf-loss in mice leads to tumor development, this has been
attributed primarily to impaired apoptosis while studies examining the role of p19Arf
during development indicate that it plays a critical role in determining the balance
between the rate of proliferation and apoptosis. Published studies investigating the loss
of p19Arf in mouse embryonic fibroblasts (MEFs) show that these cells arrest in
response to DNA damage and can also bypass senescence during aging. However,
there are no studies that have investigated the loss of p19Arf in adult fibroblasts. My
work indicates that loss of p19Arf in adult lung fibroblasts are resistant to amino acid
deprivation (AAD) primarily due to increased proliferation of p19Arf-/- cells in the absence
of p53-mediated activation of cell cycle checkpoints. This rapid proliferation of p19Arfnull cells render these cells to be highly dependent on autophagy for survival during LD.
This increase in fibroblast survival is tumor promoting in vivo as xenograft tumor models
with wild-type (WT) p19Arf show increased tumor growth when transplanted into the
flank of p19Arf -null mice, with loss of p19Arf in cells in the TME. The novelty of my
work has identified a role for p19Arf in the fibroblasts in the TME, in addition to its
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upregulation in response to prolonged LD. Future directions include investigating the
effects of p19Arf reintroduction into the stroma of the TME on tumor progression, and its
role in inhibiting tumor progression in the context of p53 deficiency. Future studies
should also include investigating the role of p14ARF in the TME of human cancers.
Our work on endothelial cells in the TME in response to shear stress has
identified an alternative approach to tumor vascular normalization to increase the
efficacy of chemotherapy. My studies suggest that a single bout of acute exercise may
enhance chemotherapeutic efficacy if drugs are administered immediately after a single
session of aerobic exercise. My work demonstrates that attenuation in tumor growth
rates occurs independent of tumor vasculature normalization and may be attributed to
increased blood flow leading to more effective drug delivery to tumor beds. Future
studies investigating acute exercise should investigate the mechanism underlying how
acute exercise before treatment slows tumor growth and the effect of acute exercise on
activation of endothelial signaling pathways.
My studies investigating the effect of increased expression of peroxisome
proliferator-activated receptor gamma coactivator 1 alpha (PGC1-α) in skeletal muscles
showed no effect on tumor growth rates or metastatic progression when exposed to
chronic exercise. These studies did show that chronic exercise increased metastatic
progression in both wild-type and PGC1- α transgenic mice. Although this effect was not
specific to overexpression of PGC1-α in skeletal muscles, future studies should
investigate the role of PGC1-α overexpression in chemotherapeutic efficacy in other
cancer models with and without either chronic or acute aerobic exercise.
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P19Arf is induced in fibroblasts in response to prolonged leucine deprivation
My work shows that primary lung fibroblasts promote tumor growth in response
to stresses of the TME. In this study we showed that the loss of p19Arf in adult lung
fibroblasts enhanced tumor growth rates of sarcoma cells with WT p19Arf. A caveat to
our mouse studies is that the loss of p19Arf occurred in all cell types including immune
cells such as macrophages. Other groups have shown that p19Arf is required to prevent
the transition of tumor suppressing type-I macrophages from becoming type-II, tumor
promoting macrophages16. To address the effect of p19Arf loss specifically in fibroblasts, I
utilized a 3D tumoroid model to limit the effect of tumor cell growth to primary lung
fibroblasts. I generated 3D tumoroids by resuspending tumor cells and primary adult
lung fibroblasts (ALFs) in Basement Membrane Extract (BME) that promote the
formation of 3D-tumors with fibroblasts intercalating throughout the tumoroids. Using
this system, we showed that the loss of p19Arf in primary lung fibroblasts enhanced
overall cell number that was further increased during LD. The increase in fibroblasts was
associated with an increase in the number of actively proliferating α-SMA positive
fibroblasts. While the deprivation of many essential amino acids is a common stress in
the TME due to the rapid proliferation of tumor cells and overall nutrient deprivation in
the TME, deprivation of the essential amino acid leucine was utilized in my experimental
systems because of its potent effect on suppressing activation of the mTOR pathway
during long-term LD and its inhibition of cancer cell survival53,126,127.
My data reveal the novel finding that prolonged LD induced p19Arf expression
and activation of the integrated stress response (ISR) pathway in fibroblasts. ISR
activation was even further increased in the absence of p19Arf. Interestingly, I found
elevated levels of phosphorylated eIF2-α at baseline in both WT and p19Arf -/- primary
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fibroblasts. One potential explanation could be an artefact of tissue culture as fibroblasts
are activated in tissue culture due to the stiffness of tissue culture plastic. Studies have
shown increased fibroblast activation on stiff substrates with tissue culture plastic logfold stiffer than the extracellular matrix that fibroblasts are exposed to in vivo. This likely
induced stress that was independent of AAD as the phosphorylation of eIF2-α is not
exclusive to this stress128. Despite the baseline activation of the ISR in both WT and
p19Arf-null fibroblasts, my studies focused on investigating the effect of LD on fibroblast
activation and the role of p19Arf.
In this study I show that the loss of p19Arf increased fibroblast function and
survival during prolonged LD through increased proliferation that persisted during longterm exposure to stress. I confirmed that the increased proliferation rate of p19Arf-null
fibroblast was sufficient to maintain fibroblast survival during long-term LD as the
increased proliferation rate was greater than the rate of apoptosis. The treatment of
p19Arf-null fibroblasts with mitomycin C (Mito C) to inhibit cellular proliferation revealed
the dependence on increased proliferation of p19Arf-null fibroblasts for survival during
long-term LD. My data also found that increased fibroblast activation and function
continued during prolonged LD. My data show an increase in collagen invasion by
p19Arf-null fibroblasts although the number of cells that migrated entirely through the
collagen bed was limited. Thus it is possible that the collagen gel prevented a nutrient
gradient between cells in a serum-free chamber to the nutrient replenished media. It
would be of interest to assess migration of p19Arf-null fibroblasts as compared to WT
fibroblasts in the presence of tumor-conditioned media. I utilized a hydroxyproline assay
to quantify collagen production by measuring hydroxyproline as a surrogate for collagen
levels. I measured hydroxyproline in conditioned media from p19Arf-null and WT
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fibroblasts during invasion assays. However, fibroblast invasion in this context does not
necessarily require an increased production of collagen but instead the degradation of
collagen that is required for cells to migrate through the collagen bed. Thus my data
indicate a decrease in hydroxyproline in conditioned media collected from p19Arf-null
fibroblast invasion assays as compared to WT fibroblast invasion assay. It would be of
interest to compare the rate of collagen deposition by treating fibroblasts with ascorbic
acid, which forces the production of collagen by these cells39,129. The loss of p19Arf did
not prevent apoptosis as measured by Annexin V during prolonged stress and I saw no
differences in cell death between WT and p19Arf fibroblasts. However, possible caveats
to this data are that Annexin V is an early marker of apoptosis thus may not be an
accurate indication of cell death in these populations and studies that have shown
p19Arf can induce cell death through autophagy independent of conventional apoptosis
pathways84,85,102.
Finally, my research investigated the role of autophagy as a survival mechanism
by p19Arf-null fibroblasts to cope with prolonged LD. My data shows increased utilization
and dependence on autophagy pathways to survive this long-term stress. At baseline, I
show increased expression of the two autophagy markers p62 and LC3-II in p19Arf -/fibroblasts when compared with WT fibroblasts that was maintained when exposed to
prolonged LD. We also confirmed the necessity of autophagy through treatment with the
autophagy inhibitor bafilomycin preventing lysosomal degradation of LC3-II revealing
increased levels in p19Arf -/- fibroblasts at later time points indicating an increase in
autophagic flux. Since bafilomycin treatment and probing for LC3-II expression is an
efficient readout to indicate differences in autophagic flux, further studies should
compare the amount of lysosomal LC3-II between groups through the labelling of LC3
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with the mCherry-GFP marker. It would also be of interest to determine how p19Arf
effects the expression of autophagy-related genes, such as ATG5, and how their
deletion affects p19Arf -/- fibroblast survival during LD. Overall, our data indicate that the
p19Arf tumor suppressor plays a role in the ISR pathway in primary fibroblasts to induce
apoptosis during prolonged AAD to inhibit tumor progression.

Future directions to identify the effects the loss of stromal p19Arf in vivo
Moving forward, identifying the role of p19Arf and the ISR pathway in primary
fibroblasts should be further investigated in vivo and in human cells in response to
prolonged LD. While antibodies specific for mouse phosphorylated GCN2 (P-GCN2) are
not available, a human-specific P-GCN2 antibody is commercially available and can be
utilized on human fibroblasts that lack p14ARF that have been exposed to prolonged LD
to compare activation of the ISR. It would also be of interest to compare levels of ATF4
in the context of p19Arf -/- in response to stress in the TME. While most studies have
studied ATF4 in the context of total protein expression, notably, nuclear ATF4 is the
activated form of the protein and is an indication of its activity level in addition to mRNA
levels130. In vivo, studies investigating the role p19Arf in the TME could be further
explored by targeting p19Arf utilizing a tissue specific and inducible model to
conditionally delete exon 2 of CDKN2A to specifically target p19Arf, and not p16Ink4131.
While my thesis research has focused on the deprivation of leucine to primary
fibroblasts, future studies would also investigate not only the other essential and
conditional-essential amino acids, but also other stresses of the TME . Previous studies
have shown that mice on a leucine-free diet can prevent the growth of breast cancer
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xenograft53, thus it would be of interest to utilize a leucine-restricted diet for mice with a
fibroblast specific deletion of p19Arf and determine its effects on tumor progression.
Additionally, certain cancer types are more reliant on autophagy to promote tumor
progression, thereby presenting a targetable, therapeutic window. Rangwala et al., have
shown in phase I clinical trials that the utilization of hydroxychloroquine in combination
with temozolomide, an anti-tumor alkylating agent, in a final dose cohort had a complete
response and prolonged stable disease in melanoma patients132. Combining both a
leucine restricted diet to create a greater dependence on autophagy, together with
hydroxychloroquine and chemotherapy could enhance the effectiveness of cancer
treatment.
Future studies should also investigate the role of LD on activation of the mTOR
pathway in fibroblasts of the TME and the role of the p19Arf tumor suppressor. While a
previous study has shown that deletion of p19Arf is necessary to maintain activation of
the mTOR pathway, it would be of interest to determine if p19Arf -/- fibroblasts are reliant
on mTOR during stress to determine its potential as a therapeutic target95. In this current
study, I primarily investigated overall induction of autophagy, but there are varying types
of autophagy that occur within the cell. Other types of autophagy should also be
investigated in greater depth considering the localization of the p19Arf isoform, smARF
to the mitochondria. It would be of interest to determine if smARF played a role in the
regulation and processing of mitophagy in cancer133–135 and to also determine if smARF
plays a role in the process of mitochondrial fission and fusion, and whether it is altered in
cancer136,137. Future studies should also investigate the recycling of the ribosome,
ribophagy138–140, not only due to its role in cancer progression, but also because of
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previous studies that have shown that one of the p53-independent functions of p19Arf
including the regulation of ribosome biogenesis94,141.

Acute exercise provides therapeutic window
My work has shown an intervention by which a single session of aerobic exercise
prior to the administration of the chemotherapy drug doxorubicin (Dox) was sufficient to
attenuate melanoma growth rates in vivo. Interestingly, the administration of Dox prior to
exercise had no effect on tumor growth and even showed an increase in tumor growth
rates in mice when compared with their sedentary control counterparts. One reason for
this may be the altered rate of metabolism when the drug is administered. Although our
group has previously shown that the presence of Dox within the tumor is increased when
mice were subject to a chronic exercise regimen, we also showed that Dox levels in the
tumor bed were similar in the acute exercise group as compared with our sedentary
group when Dox waa administered before exercise25. Further studies should also
quantify the amount of Dox present within the tumor when administered after exercise. It
is possible that the administration of drug prior to exercise led to increased clearance of
Dox due to aerobic exercise-mediated increase in shear stress. Further studies should
also measure the amount of drug in the liver to compare the clearance rate of Dox. The
effects of acute aerobic exercise may be limited to specific drugs as our data did not see
any difference when the drug Gemcitabine was administered either before or after
exercise in our pancreatic cancer xenograft mouse model. Since the addition of exercise
has been prescribed to enhance the quality of life of pancreatic cancer patients, we
anticipated that exercise would alter pancreatic tumor growth142. However, the xenograft
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model we utilized inoculated syngeneic murine pancreatic ductal adenocarcinoma cells
into the flanks of WT mice and this tumor model has limited physiologically relevance to
pancreatic cancer patients. Further studies should utilize one of the many wellcharacterized genetically engineered mouse models of pancreatic cancer that closely
recapitulates the clinical course of pancreatic cancer. Future studies should also
investigate other tumor types to determine whether aerobic exercise could be beneficial.
Additionally, to quantify the extent of shear stress-induced by acute exercise, endothelial
nitric oxide synthase can be measured within the tumor and other tissues to determine
how one session of acute exercise alters shear stress.

Future directions to investigate chemotherapeutic efficacy during acute exercise
Overall, this study has revealed acute aerobic exercise as an approach to
potentially increase chemotherapy efficacy in vivo. Future studies will investigate
activation of the calcineurin-NFAT pathway in endothelial cells to determine whether it is
altered in response to acute exercise. Studies to determine the role of the unfolded
protein response (UPR) in endothelial cells in response to increased shear stress would
also be of great interest. As mentioned in Chapter 1, the UPR pathway is activated in
response to changes in calcium levels and thapsigargin is a drug utilized to stress the
endoplasmic reticulum (ER) by depleting calcium within cells. Readouts of the ER stress
pathway include activation of PKR-like ER kinase (PERK) resulting in activation of the
ISR pathway. One caveat to this could be the overlapping stresses inducing activation of
the ISR as shear stress may also activate the heme-regulated eIF2α kinase (HRI) arm of
the ISR pathway, and even conditional deletion of specific arms of the ISR may lead to
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compensation as previous work has shown in the context of glutamine deprivation61.
While anti-VEGF therapies and chronic exercise provide approaches for tumor vascular
normalization and increasing tumor susceptibility to chemotherapy, perhaps the
utilization of anti-VEGF therapy combined with acute exercise would also lead to
increased chemotherapy efficacy. A caveat to this is that the increased amount of VEGF
produced during exercise may be utilized by the tumor to promote growth. While this
poses a potential conflict, utilizing low doses of anti-VEGF therapy to sequester VEGF
combined with the increased circulation of the chemotherapeutic agent following acute
exercise may provide similar benefits to chronic exercise.

PGC1-α overexpression has no effect on tumor progression
In collaboration with the Arany lab, I have shown that peroxisome proliferatoractivated receptor gamma coactivator 1 alpha (PGC1-α) overexpression in skeletal
muscle has no effect on tumor growth rates or metastasis to the lungs of mice during
exercise. In this model, the use of transgenic mice that overexpressed PGC1-α in
skeletal muscles were compared to WT littermate control mice. Both cohorts of mice
were inoculated with LLC tumor cells in their flanks with tumors resected after reaching
500mm3 volume before initiating a chronic aerobic exercise program for two weeks. After
this time period, mice were euthanized and examined for lung metastasis with no
significant differences observed between experimental and control cohorts. Future
studies could alter the experimental model such that primary tumors were resected at
smaller volumes or the use of slower growing tumor cells to ensure that tumors were still
fully encapsulated at the time of resection. While these experiments indicate that PGC162

α overexpression in skeletal muscles do not have an effect on tumor growth and
metastasis, it would be of interest to compare the effects that overexpression of PGC1-α
or other members of the PPAR family in cell types within the TME may have on tumor
progression.

Future directions to investigate the role of PGC1-α on chemotherapeutic efficacy
While PGC1-α plays a critical role in cellular metabolism, it would be of interest to
combine chemotherapeutic treatment of tumor bearing mice with our single session
acute exercise model to determine if the enhanced metabolism by these mice allows for
increased clearance or penetrance of the drug within a tumor bed. Future studies
comparing the effects of chronic or acute exercise on tumor growth and progression on
the background of PGC1-α overexpression will be of great interest.

Clinical Implications
Expression levels of the p14ARF tumor suppressor has been suggested to serve
as a marker of tumor progression in certain cancer models 143. In this study I’ve shown
that AAD induces expression of p19Arf expression in primary lung fibroblasts. While
p14ARF has been reported to function in either a tumor suppressing or promoting
manner depending on the context and on the specific cancer type90,135, my work
demonstrates that the p19Arf mouse homolog functions in fibroblasts in the TME to
suppress tumor growth and that its loss or potential silencing in fibroblasts in the TME
enhances tumor growth and fibroblast function and survival through autophagy. My
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research suggests that the role of classic tumor suppressors should be further
investigated in cellular populations in the TME. I have also shown that acute exercise
increases therapeutic efficacy when administered after exercise. This timing of drug
delivery, before or after acute exercise, may have important clinical applications as a
single bout of brisk walking on a treadmill prior to drug infusion may be a feasible
intervention for cancer patients undergoing chemotherapy. Future studies could identify
the cancer types that may be susceptible to acute exercise combined with chemotherapy
and this approach could be tested in a clinical trial for patients willing and able to
undertake acute exercise during chemotherapy.
In conclusion, my thesis work has shown a role for p19Arf in response to AAD in
the TME that suppresses tumor growth through regulating fibroblast survival and
activation. While the deletion of the P19Arf in the TME may not be physiologically
relevant, it is possible that p14ARF expression may be epigenetically silenced and
should be investigated. My thesis research has also shown that a single session of
acute aerobic exercise followed by chemotherapy treatment was sufficient to suppress
tumor growth, which can lead a feasible intervention for cancer patients.
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CHAPTER 6: Material and Methods

Primary lung fibroblasts isolation and culture
Fibroblasts were cultured in DMEM-F12 + L-glutamine (Gibco) with 10% heat inactivated
FBS, L-glutamine, and penicillin-streptomycin. To isolate primary lung fibroblasts, lungs
from male and female 3-5-week-old mice were minced into small pieces with scissors
then dissociated in Hank’s buffered saline solution (HBSS) containing 5 mg/ml type II
collagenase and 0.5 mg/ml deoxyribonuclease I (Worthington, #LS004176 and
#LS002139) with shaking in Thermo Scientific MaxQ 5000 floor shaker at 37°C at 250
rotations per minute for 45 minutes. Dissociated lungs were passed through 100μm and
40μm filters to obtain a single cell suspension before resuspending in culture media and
plating; fibroblasts were allowed to adhere for 1-2 hours at 37°C before non-adherent
cells were washed off. Fibroblast identity was confirmed by immunostaining cultured
cells for vimentin (goat, Santa Cruz #sc-7557, 1:100), CD45.2 (biotinylated mouse, BD
Pharmingen #553771,1:100), and CD31 (rat, BD Pharmingen #553370, 1:100), followed
by secondary antibody and streptavidin (Alexa Fluor 647 anti-goat IgG, Alexa Fluor 488
anti-rat IgG, Alexa Fluor 555 streptavidin, all 1:100: Invitrogen #A-21447, A-11006,
Thermo Fisher #S-21381 respectively); fibroblasts were >99% vimentin-positive, with
<5% CD45+ contaminants and no CD31+ cells present.
Western blot
Cells were lysed in radioimmunoprecipitation assay buffer (RIPA, 50 mmol/L TrisHCl pH 8, 150 mmol/L NaCl, 1% Triton-X, 0.5% sodium deoxycholate, and 0.1% SDS)
containing a protease inhibitor cocktail followed by centrifugation at 16,000 x g for 10
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minutes, and supernatant was collected. Total protein content was quantified using BCA
assay (Thermo Scientific). Protein loading of fibroblast lysates was normalized using the
protein standard curve in the Bio-Rad Protein Assay Kit on samples diluted 1:10. Total
protein from fibroblast lysates was analyzed by running samples in 4x Laemmli sample
buffer (Bio-Rad) on a 4-12% gradient gel (GenScript). SDS-PAGE of lysates was
performed using 5-20μg per sample at 100-110 V on 8, 10, or 12% gels depending on
the size of the protein in question using the Bio-Rad Mini Protean Tetra Cell system.
Proteins were transferred onto PVDF membranes at 100 V for 1 hour using the Bio-Rad
Mini Trans-Blot system. Blots were blocked in 5% non-fat dry milk (LabScientific M0841) or 5% BSA (Roche, 03-116-956-001)in TBS-T (TBS + 0.1% Tween 20) and
incubated with primary antibody diluted in blocking buffer at 4° C overnight (p19ARF :
1:500, Novus Biologicals #NB200-174;; temperature (p19ARF (1:500; Novus Biologicals
; #NB200-174), ATF4 (1:1000; Cell Signaling Technology; #11815), phospho-eIF2a
(Ser51) (1:500; Cell Signaling Technology; #3597) total-eIF2a (1:1,000; Cell Signaling
Technology; #9722), LC3B (1:1,000; Cell Signaling Technology; #2775S), p62 (1:1,000;
Cell Signaling Technology; #5114), and NBR1 (1:1,000; Cell Signaling Technology; #
9891). Anti-Beta tubulin (1: 1,000; # 2128) and a-actin (1:10,000, Sigma #A2668) was
used as loading control. Blots were washed in TBS-T, and secondary antibodies
(Horseradish peroxidase–conjugated anti-rabbit (1:2,000; Cell Signaling; #7074), antimouse (1:2,000; Cell Signaling Technology; #7076), or goat anti-rat (1:2,000; Cell
Signaling Technology; #7077) were incubated in blocking buffer for 1-2 h at room
temperature then washed with TBS-T. Bands were visualized using enhanced
chemiluminescence reagent (100 mM Tris pH 8.6, 0.2 mM p-coumaric acid, 1.25 mM
luminol, 2.6 mM).
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Subcutaneous xenografts
All animal experiments and subcutaneous (s.c.) xenografts were approved by the
Institutional Animal Care and Use Committee at the University of Pennsylvania. Six wildtype and 6 p19Arf -/- (3 male and 3 female mice per group) mice between 6 and 8 weeks
old (purchased from Jackson Laboratory) had 1.34 × 105 SKPY cells implanted s.c. in
their flanks. Prior to injection, cells were grown in complete media (DMEM containing
10% FBS). Cells were collected, resuspended in ice-cold serum-free DMEM for injection.
For co-injection experiments, a total of 3.75 x 105 cells (lung fibroblasts: LLC 1:1) were
resuspended in ice-cold serum-free media and mixed with Basement Membrane Extract
(Millipore Sigma, #3533-005-02) at a ratio 1:1. The final volume per injection for each
experiment was 200μL. For acute exercise experiments, animals received 300,000
melanoma (B16F10) or pancreatic ductal adenocarcinoma (PDAC 4462) to their
subcutaneous flank and tumors were allowed to grow for 10 days. Mice received
doxorubicin (2mg/kg) or gemcitabine (15mg/kg) chemotherapies for melanoma or
pancreatic cancer models, respectively, before exercise on day 11 via intraperitoneal
injections. Tumor bearing mice were exercised for 60 minutes at a pace of 12m/min
using the Columbus Instruments Exer 3/6 Animal treadmill and were returned to housing
to have tumor volume measured by calipers until the experimental endpoint. For PGC1-α
transgenic mice tumor experiments, mice were provided by Dr. Zolt Arany (Perelman
School of Medicine, University of Pennsylvania). PGC1-α transgenic and WT mice
received 1x106 Lewis Lung Carcinoma (LLC) cells inoculated subcutaneously in their
flank and tumor volume monitored using calipers. Tumors were surgically resected when
they reach 500-800mm3 in volume. After three days of recovery, mice were exercised
for 45 minutes at a pace of 12m/min 5 times a week for two weeks. After the final
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exercise session, mice were sacrificed, and lungs were inflated with formalin followed by
paraffin embedding. Tumor volumes were recorded at the indicated timepoints using
caliper measurements. The formula, V = (L)(W2) (π/6), was used to calculate tumor
volume. Tumors were harvested and flash frozen in OCT compound for further analyses.
Aerobic Exercise
Mice were inoculated with 300,000 tumor cells in 200μl PBS subcutaneously in the flank.
When tumors reached ~100 mm3 (4–7 days post injection) or the indicated volume, mice
began treatment. For both B16F10 and PDAC tumor-bearing mice, acute exercise plus
chemotherapy groups performed one session of 60 minutes of treadmill running once at
12 m/min. For PDAC tumor-bearing mice, gemcitabine was delivered once by
intraperitoneal (IP) injection before or after exercise. For B16F10 tumor- bearing mice,
acute exercise plus doxorubicin groups performed one session of 60 minutes of treadmill
running at 12 m/min. Mice received 2 mg/kg of doxorubicin by tail vein injection before or
after exercise. After the final tumor measurement, mice were euthanized, and tumors
were harvested and frozen in OCT.
Tumoroid Assay
Tumor cells were resuspended in Basement Membrane Extract (BME) and layered onto
a BME bed containing fibroblasts then exposed to complete or leucine deprived media.
Three-dimensional tumoroids were imaged every two days for a week, with cell numbers
and sizes were quantified. Tumoroids were collected and dissociated to acquire single
cell suspension, concentrated via cytospin and stained for Ki67 and alpha smooth
muscle actin (α-SMA) (1:100, Abcam, #56947). Alexa Fluor 488-donekyt-anti-sheep IgG
(1:500, Novus Biologicals, #NBP1-75446), Alexa Fluor 594-goat-anti-rabbit IgG.
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Fluorescent images were captured with a laser scanning confocal microscope. Confocal
imaging was performed on a Leica TCS SP5 and processed using LAS AF software.
GCN2 Inhibition
Fibroblasts were treated with GCN2-IN-1 (MedChem Express HY-100877) at a final
concentration of 1µM in leucine deprived media overnight and cells harvested for
analysis.
Autophagy Inhibition
Fibroblasts were exposed to leucine deprived media and exposed to Bafilomycin
(Cayman Chemicals #11038) at a final concentration of 1nM in DMSO 2 hours before
harvesting lysates and probing for LC3. In survival assays, fibroblasts were treated
chloroquine (Sigma-Aldrich # C6628) at a final concentration of 100nM in leucine
deprived media for the times indicated.
Cell Cycle Arrest
Fibroblasts were treated with Mitomycin C (Sigma Aldrich #M4287-2MG) at a final
concentration of 4µg/mL in culture media and incubated for 6 hours before washing with
cells replated in complete media. Cell cycle arrest was confirmed by the absence of EdU
incorporation.
Migration Assay
Cells were grown to confluency in 12-well plates in triplicate. A scratch was generated
with a 200-μL tip across each well and pictures taken at the starting timepoint, and at 2-4
hour increments post-scratch until complete scratch closure. The percentage of area that
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was “repaired” was measured using ImageJ software and plotted as the average of the
triplicates with standard deviation (SD). Experiments were repeated three times.

qRT-PCR
Total RNA was processed and extracted with TrIzol reagent (Life Technologies, catalog
no. 15596018) and Direct-zol RNA MicroPrep Kit (Zymo Research, #R2060). RT
reaction was performed using High-Capacity RNA-to-cDNA Kit (Applied Biosystems,
#4387406). qRT-PCR was then performed using SYBR Green Master Mix (Bimake,
#B21202) and a ViiA7 Real-Time PCR Instrument (Applied Biosystems). SYBR probes
were used to quantify the expression of p19Arf (Forward: 5’ AGA GGA TCT TGA GAA
GAG GGC C 3’; Reverse: 5’ GCA GTT CGA ATC TGC ACC G 3’). Normalization was
performed using the housekeeping genes 18S (Forward: 5’
CAATTACAGGGCCTCGAAAG 3’; Reverse: 5’AAACGGCTACCACATCCAAG).
Samples were performed in triplicate with each experiment repeated twice.

Hydroxyproline assay
Media was collected from transwells during collagen invasion assays 48 hours postplating . Hydroxyproline levels were measured using the colorimetric Hydroxyproline
Assay Kit (Sigma-Aldrich, #MAK0081KT) per manufacturer’s instructions to determine
hydroxyproline content as a surrogate for collagen levels.
Immunostaining
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Cells were seeded onto sterile round coverslips (12 mm) on parafilm covered 10cm
dishes at a density of 12,500 cells per coverslip. Cells were cultured in their respective
media at 37°C, 5% CO2 for the times indicated. After treatment, EdU proliferation assays
were performed with Click-iT EdU Alexa Fluor 594 Imaging Kit (Invitrogen, #C10339)
according to manufacturer's instructions; fibroblasts were pulsed with 10 mM EdU for
16–18 hours before fixation and staining. Coverslips were mounted face-down onto
microscope slides using Vectashield anti-fade mounting medium (Vector Laboratories).
Images were acquired with laser scanning microscope Zeiss LSM 510 with 63 ×
objective lens (Carl Zeiss AG). All microscope parameters were held constant across
samples. At least nine different areas were imaged per sample.

Statistical analysis
Statistical analyses were performed using GraphPad Prism version 8 software, using
unpaired Student two-tailed t test. Data are presented as mean ± SEM of at least three
independent experiments unless indicated that standard deviation was used. Statistical
significance was defined as ***, P < 0.001; **, P < 0.01; *, P < 0.05; n.s., not significant.
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